Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia (scientific article)

cites work (P2860)

Q41842929	"Cell biology meets physiology: functional organization of vertebrate plasma membranes"--the immunological synapse
Q37201423	"Model t" cells: a time-tested vehicle for gene therapy
Q38723957	"NextGen" Biologics: Bispecific Antibodies and Emerging Clinical Results
Q47849932	'Atypical' CAR T cells: NKG2D and Erb-B as examples of natural receptor/ligands to target recalcitrant solid tumors
Q39136403	'Final common pathway' of human cancer immunotherapy: targeting random somatic mutations.
Q48093699	3D microvascular model recapitulates the diffuse large B-cell lymphoma tumor microenvironment in vitro.
Q34180031	4-1BB (CD137), an inducible costimulatory receptor, as a specific target for cancer therapy
Q35690389	4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors
Q59134955	4-1BB enhancement of CAR T function requires NF-κB and TRAFs
Q33884816	5T4-specific chimeric antigen receptor modification promotes the immune efficacy of cytokine-induced killer cells against nasopharyngeal carcinoma stem cell-like cells
Q41961217	A CD22-reactive TCR from the T-cell allorepertoire for the treatment of acute lymphoblastic leukemia by TCR gene transfer.
Q36709308	A Chimeric Switch-Receptor Targeting PD1 Augments the Efficacy of Second-Generation CAR T Cells in Advanced Solid Tumors
Q92769536	A DNA vaccine expressing an optimized secreted FAPα induces enhanced anti-tumor activity by altering the tumor microenvironment in a murine model of breast cancer
Q90050652	A Distinct Subset of Highly Proliferative and Lentiviral Vector (LV)-Transducible NK Cells Define a Readily Engineered Subset for Adoptive Cellular Therapy
Q45870245	A Fusion Receptor as a Safety Switch, Detection, and Purification Biomarker for Adoptive Transferred T Cells
Q34480145	A Multidrug-resistant Engineered CAR T Cell for Allogeneic Combination Immunotherapy
Q57025289	A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization
Q50032634	A Rational Strategy for Reducing On-Target Off-Tumor Effects of CD38-Chimeric Antigen Receptors by Affinity Optimization.
Q59789472	A Review on Electroporation-Based Intracellular Delivery
Q35976599	A T-cell-directed chimeric antigen receptor for the selective treatment of T-cell malignancies
Q42119020	A TLR and non-TLR mediated innate response to lentiviruses restricts hepatocyte entry and can be ameliorated by pharmacological blockade
Q56889692	A comprehensive review on the role of co-signaling receptors and Treg homeostasis in autoimmunity and tumor immunity
Q37362636	A cytokine cocktail directly modulates the phenotype of DC-enriched anti-tumor T cells to convey potent anti-tumor activities in a murine model.
Q93253601	A dynamic interaction between CD19 and the tetraspanin CD81 controls B cell co-receptor trafficking
Q36057568	A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR.
Q36356392	A fully human chimeric antigen receptor with potent activity against cancer cells but reduced risk for off-tumor toxicity
Q36942027	A genome editing primer for the hematologist
Q95319497	A guide to cancer immunotherapy: from T cell basic science to clinical practice
Q41139635	A lentiviral vector-based therapeutic vaccine encoding Ag85B-Rv3425 potently increases resistance to acute tuberculosis infection in mice
Q36062047	A long road of T-cells to cure cancer: from adoptive immunotherapy with unspecific cellular products to donor lymphocyte infusions and transfer of engineered tumor-specific T-cells.
Q93080047	A nanoparticle-incorporated STING activator enhances antitumor immunity in PD-L1-insensitive models of triple-negative breast cancer
Q26849476	A new approach to gene therapy using Sleeping Beauty to genetically modify clinical-grade T cells to target CD19
Q42544252	A new cellular weapon to kill leukaemic B-cells
Q94526279	A new hope
Q37555940	A new insight in chimeric antigen receptor-engineered T cells for cancer immunotherapy
Q61808044	A novel CD7 chimeric antigen receptor-modified NK-92MI cell line targeting T-cell acute lymphoblastic leukemia
Q47549907	A novel Epstein-Barr virus-latent membrane protein-1-specific T-cell receptor for TCR gene therapy
Q27345360	A novel ex vivo isolation and expansion procedure for chimeric antigen receptor engrafted human T cells
Q87969904	A novel method to generate T-cell receptor-deficient chimeric antigen receptor T cells
Q38629690	A novel signature for stratifying the molecular heterogeneity of the tissue-infiltrating T-cell receptor repertoire reflects gastric cancer prognosis
Q37064737	A pharmacologic perspective on newly emerging T-cell manipulation technologies
Q50794802	A phase I clinical trial combining dendritic cell vaccination with adoptive T cell transfer in patients with stage IV melanoma.
Q36226627	A phase I clinical trial of adoptive transfer of folate receptor-alpha redirected autologous T cells for recurrent ovarian cancer.
Q45119837	A phase I trial of NK-92 cells for refractory hematological malignancies relapsing after autologous hematopoietic cell transplantation shows safety and evidence of efficacy
Q37499778	A pliable electroporation patch (ep-Patch) for efficient delivery of nucleic acid molecules into animal tissues with irregular surface shapes
Q61443124	A rapid in vitro methodology for simultaneous target discovery and antibody generation against functional cell subpopulations
Q37376346	A role for multiple chimeric antigen receptor-expressing leukocytes in antigen-specific responses to cancer
Q90215725	A safe and potent anti-CD19 CAR T cell therapy
Q41475288	A sensitivity scale for targeting T cells with chimeric antigen receptors (CARs) and bispecific T-cell Engagers (BiTEs).
Q37358371	A simple and effective method to generate lentiviral vectors for ex vivo gene delivery to mature human peripheral blood lymphocytes
Q45946525	A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma.
Q53591514	A special issue on cancer immunotherapy.
Q42292505	A strategy to identify linker-based modules for the allosteric regulation of antibody-antigen binding affinities of different scFvs
Q33692070	A tandem CD19/CD20 CAR lentiviral vector drives on-target and off-target antigen modulation in leukemia cell lines
Q34030602	A universal strategy for adoptive immunotherapy of cancer through use of a novel T-cell antigen receptor
Q34047977	A versatile system for rapid multiplex genome-edited CAR T cell generation
Q59791008	Aberrant RNA Splicing in Cancer and Drug Resistance
Q52646462	Accurate control of dual-receptor-engineered T cell activity through a bifunctional anti-angiogenic peptide.
Q26827701	Acquired and intrinsic resistance in cancer immunotherapy
Q60044328	Activated iNKT cells enhance the anti-tumor effect of antigen specific CD8 T cells on mesothelin-expressing salivary gland cancer
Q38726937	Activation induced cell death (AICD) of human melanoma antigen-specific TCR engineered CD8 T cells involves JNK, Bim and p53.
Q38095113	Acute lymphoblastic leukemia in adults: encouraging developments on the way to higher cure rates
Q33680320	Adapting in vitro embryonic stem cell differentiation to the study of locus control regions
Q38576508	Adoptive Cell Therapy--Tumor-Infiltrating Lymphocytes, T-Cell Receptors, and Chimeric Antigen Receptors.
Q37242561	Adoptive Immunotherapy For Leukemia With Ex vivo Expanded T Cells
Q36129903	Adoptive Immunotherapy in Postoperative Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis.
Q38603686	Adoptive T Cell Therapies: A Comparison of T Cell Receptors and Chimeric Antigen Receptors
Q35081485	Adoptive T cell immunotherapy for cancer.
Q37519025	Adoptive T cell therapy promotes the emergence of genomically altered tumor escape variants
Q37257207	Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology
Q26782845	Adoptive T-Cell Immunotherapy
Q26775720	Adoptive T-cell therapies for refractory/relapsed leukemia and lymphoma: current strategies and recent advances
Q27006934	Adoptive T-cell therapy for Leukemia
Q26800611	Adoptive T-cell therapy for cancer: The era of engineered T cells
Q38172451	Adoptive T-cell therapy for hematological malignancies using T cells gene-modified to express tumor antigen-specific receptors
Q42962721	Adoptive T-cell therapy to treat liver cancer: is the liver microenvironment key?
Q38525029	Adoptive T-cell therapy: a need for standard immune monitoring.
Q34511623	Adoptive T-cell therapy: adverse events and safety switches
Q38068968	Adoptive T-cell transfer in melanoma
Q52671132	Adoptive cancer immunotherapy using DNA-demethylated T helper cells as antigen-presenting cells.
Q27009541	Adoptive cell therapy for sarcoma
Q92735578	Adoptive cell therapy using engineered natural killer cells
Q38146713	Adoptive cell transfer for patients with metastatic melanoma: the potential and promise of cancer immunotherapy.
Q34717795	Adoptive cellular immunotherapy in metastatic renal cell carcinoma: a systematic review and meta-analysis
Q93337436	Adoptive cellular therapies: the current landscape
Q38258842	Adoptive cellular therapy of cancer: exploring innate and adaptive cellular crosstalk to improve anti-tumor efficacy
Q26795540	Adoptive immunotherapy for acute leukemia: New insights in chimeric antigen receptors
Q38178359	Adoptive immunotherapy for cancer or viruses
Q38170496	Adoptive immunotherapy for cancer.
Q28262548	Adoptive immunotherapy for cancer: harnessing the T cell response
Q38291751	Adoptive immunotherapy for hematological malignancies using T cells gene-modified to express tumor antigen-specific receptors
Q39045586	Adoptive immunotherapy for the treatment of glioblastoma: progress and possibilities
Q38032141	Adoptive immunotherapy of advanced melanoma
Q38170501	Adoptive immunotherapy with genetically modified lymphocytes in allogeneic stem cell transplantation
Q38786628	Adoptive therapy with CAR redirected T cells for hematological malignancies
Q38525034	Adoptive therapy with CAR redirected T cells: the challenges in targeting solid tumors
Q38199350	Adoptive therapy with chimeric antigen receptor-modified T cells of defined subset composition
Q41151666	Adoptive transfer of autologous T cells improves T-cell repertoire diversity and long-term B-cell function in pediatric patients with neuroblastoma.
Q36321054	Adoptive transfer of cytotoxic T lymphocytes targeting two different antigens limits antigen loss and tumor escape
Q30437670	Adoptive transfer of genetically modified Wilms' tumor 1-specific T cells in a novel malignant skull base meningioma model
Q36891101	Adoptively transferred TRAIL+ T cells suppress GVHD and augment antitumor activity
Q59043902	Adoptiver Immuntransfer und CAR-T-Zellen bei malignen Erkrankungen
Q91855043	Adult peripheral blood and umbilical cord blood NK cells are good sources for effective CAR therapy against CD19 positive leukemic cells
Q64061040	Advanced cell therapeutics are changing the clinical landscape: will mesenchymal stromal cells be a part of it?
Q39068511	Advanced generation anti-prostate specific membrane antigen designer T cells for prostate cancer immunotherapy
Q93039755	Advances and Challenges of CAR T Cells in Clinical Trials
Q48491037	Advances and issues in mantle cell lymphoma research: report of the 2014 Mantle Cell Lymphoma Consortium Workshop.
Q62746944	Advances in Chimeric Antigen Receptor T-Cell Therapies for Solid Tumors
Q90639885	Advances in Developing CAR T-Cell Therapy for HIV Cure
Q38278981	Advances in T-cell therapy for ALL.
Q38170885	Advances in chimeric antigen receptor immunotherapy for neuroblastoma
Q36508630	Advances in paediatric cancer treatment
Q38783946	Advances in personalized cancer immunotherapy.
Q38049010	Advances in the development of cancer immunotherapies
Q89128658	Advances in the use of natural receptor- or ligand-based chimeric antigen receptors (CARs) in haematologic malignancies
Q54979818	Advances on chimeric antigen receptor-modified T-cell therapy for oncotherapy.
Q28080875	Advantages and applications of CAR-expressing natural killer cells
Q36028047	Affinity-Tuned ErbB2 or EGFR Chimeric Antigen Receptor T Cells Exhibit an Increased Therapeutic Index against Tumors in Mice
Q42177990	Alkylating chemotherapy may exert a uniquely deleterious effect upon neo-antigen-targeting anticancer vaccination
Q41999433	All-trans retinoic acid and interferon-α increase CD38 expression on adult T-cell leukemia cells and sensitize them to T cells bearing anti-CD38 chimeric antigen receptors
Q37538521	All-trans retinoic acid enhances cytotoxic effect of T cells with an anti-CD38 chimeric antigen receptor in acute myeloid leukemia
Q36883904	Allelic exclusion and peripheral reconstitution by TCR transgenic T cells arising from transduced human hematopoietic stem/progenitor cells
Q37615772	Allogeneic CD19-CAR-T cell infusion after allogeneic hematopoietic stem cell transplantation in B cell malignancies
Q35904666	Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease
Q38198742	Allogeneic chimeric antigen receptor-modified cells for adoptive cell therapy of cancer
Q36461915	Allogeneic hematopoietic cell transplantation for acute lymphoblastic leukemia in adults
Q28652288	Allogeneic lymphocyte-licensed DCs expand T cells with improved antitumor activity and resistance to oxidative stress and immunosuppressive factors
Q35679601	Allogeneic stem cell transplant in patients with chronic lymphocytic leukemia with 17p deletion: consult-transplant versus consult- no-transplant analysis
Q38417073	Allogeneic stem cell transplantation in multiple myeloma: immunotherapy and new drugs.
Q50036381	Allograft for Myeloma: Examining Pieces of the Jigsaw Puzzle.
Q64965547	An Antibody Fab Fragment-based Chimeric Antigen Receptor Could Efficiently Eliminate Human Thyroid Cancer Cells.
Q38933648	An HSV-2 based oncolytic virus can function as an attractant to guide migration of adoptively transferred T cells to tumor sites
Q36787587	An NKp30-based chimeric antigen receptor promotes T cell effector functions and antitumor efficacy in vivo
Q41252003	An ROR1 bi-specific T-cell engager provides effective targeting and cytotoxicity against a range of solid tumors
Q38666304	An Update on the Use of Immunotherapy in the Treatment of Lymphoma
Q37488222	An allogeneic NK cell line engineered to express chimeric antigen receptors: A novel strategy of cellular immunotherapy against cancer
Q96762429	An effective peptide vaccine strategy circumventing clonal MHC heterogeneity of murine myeloid leukaemia
Q39031463	An efficient large-scale retroviral transduction method involving preloading the vector into a RetroNectin-coated bag with low-temperature shaking
Q34653719	An efficient low cost method for gene transfer to T lymphocytes
Q92092773	An oligo-His-tag of a targeting module does not influence its biodistribution and the retargeting capabilities of UniCAR T cells
Q38647794	An unbiased in vivo functional genomics screening approach in mice identifies novel tumor cell-based regulators of immune rejection
Q50027149	Anti-CD 19 and anti-CD 20 CAR-modified T cells for B-cell malignancies: a systematic review and meta-analysis.
Q58554673	Anti-CD19 Chimeric Antigen Receptor T Cell Therapies: Harnessing the Power of the Immune System to Fight Diffuse Large B Cell Lymphoma
Q37530579	Anti-CD19 chimeric antigen receptor T-cell therapy for adult Philadelphia chromosome-positive acute lymphoblastic leukemia: Two case reports
Q38538645	Anti-CD19 chimeric antigen receptor-modified T cells for B-cell malignancies: a systematic review of efficacy and safety in clinical trials
Q36619703	Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia
Q35146288	Anti-CD33 chimeric antigen receptor targeting of acute myeloid leukemia.
Q57024658	Anti-CD37 chimeric antigen receptor T cells are active against B- and T-cell lymphomas
Q33795137	Anti-EGFRvIII Chimeric Antigen Receptor-Modified T Cells for Adoptive Cell Therapy of Glioblastoma
Q41069286	Anti-KIT designer T cells for the treatment of gastrointestinal stromal tumor
Q37102026	Anti-leukemic potency of piggyBac-mediated CD19-specific T cells against refractory Philadelphia chromosome-positive acute lymphoblastic leukemia
Q37434176	Anti-melanoma activity of T cells redirected with a TCR-like chimeric antigen receptor
Q28390573	Anti-tumor immunity: myeloid leukocytes control the immune landscape
Q37193096	Antibodies elicited by the first non-viral prophylactic cancer vaccine show tumor-specificity and immunotherapeutic potential
Q31104000	Antibody Therapies in Cancer
Q37994136	Antibody therapy for acute lymphoblastic leukemia
Q89108141	Antibody with Infinite Affinity for In Vivo Tracking of Genetically Engineered Lymphocytes
Q27011298	Antibody, T-cell and dendritic cell immunotherapy for malignant brain tumors
Q89998321	Antibody-drug conjugates in clinical trials for lymphoid malignancies and multiple myeloma
Q37723469	Antibody-modified T cells: CARs take the front seat for hematologic malignancies
Q39243052	Antigen Discovery and Therapeutic Targeting in Hematologic Malignancies
Q27026484	Antigen-Specific T-Cell Activation Independently of the MHC: Chimeric Antigen Receptor-Redirected T Cells
Q37492464	Antigen-specific bacterial vaccine combined with anti-PD-L1 rescues dysfunctional endogenous T cells to reject long-established cancer.
Q42124330	Antigen-specific culture of memory-like CD8 T cells for adoptive immunotherapy
Q35650970	Antitumor activity from antigen-specific CD8 T cells generated in vivo from genetically engineered human hematopoietic stem cells.
Q39144346	Antitumor effects of chimeric receptor engineered human T cells directed to tumor stroma
Q88636834	Apoptosis of CD19+ chimeric antigen receptor T cells after treatment with chemotherapeutic agents
Q50027358	Application of chimeric antigen receptor-engineered T cells in ovarian cancer therapy.
Q28083907	Are BiTEs the "missing link" in cancer therapy?
Q37587972	Are chimeric antigen receptor T cells ready for prime time?
Q50042504	Armed T cells with CAR for cancer immunotherapy.
Q34153598	Armed and accurate: engineering cytotoxic T cells for eradication of leukemia.
Q34205181	Armed oncolytic virus enhances immune functions of chimeric antigen receptor-modified T cells in solid tumors
Q99711967	Arming Anti-EGFRvIII CAR-T With TGFβ Trap Improves Antitumor Efficacy in Glioma Mouse Models
Q34367252	Arming cytokine-induced killer cells with chimeric antigen receptors: CD28 outperforms combined CD28-OX40 "super-stimulation".
Q38779032	Armored CAR T-cells: utilizing cytokines and pro-inflammatory ligands to enhance CAR T-cell anti-tumour efficacy
Q37109545	Artificial antigen-presenting cells expressing AFP(158-166) peptide and interleukin-15 activate AFP-specific cytotoxic T lymphocytes
Q92025976	Artificial signaling in mammalian cells enabled by prokaryotic two-component system
Q38693642	Assessment of selected media supplements to improve F/HN lentiviral vector production yields.
Q38149725	At the Bedside: Innate immunity as an immunotherapy tool for hematological malignancies
Q48648729	Augmentation of Antitumor Immunity by Human and Mouse CAR T Cells Secreting IL-18.
Q36963494	Augmentation of CAR T-cell Trafficking and Antitumor Efficacy by Blocking Protein Kinase A Localization
Q36662079	Augmentation of anti-tumor immunity by adoptive T-cell transfer after allogeneic hematopoietic stem cell transplantation
Q33794691	Autoimmune effector memory T cells: the bad and the good
Q56897859	Autoimmunity-mediated antitumor immunity: tumor as an immunoprivileged self
Q89129502	Autologous CD19-Targeted CAR T Cells in Patients with Residual CLL following Initial Purine Analog-Based Therapy
Q54980047	B Cell Modulation Strategies in Autoimmune Diseases: New Concepts.
Q26798093	B-acute lymphoblastic leukemia/lymphoblastic lymphoma
Q29620717	B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells
Q36778126	B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma
Q94503536	B7-H3 inhibits the IFN-γ-dependent cytotoxicity of Vγ9Vδ2 T cells against colon cancer cells
Q26824446	B7-H4 as a potential target for immunotherapy for gynecologic cancers: a closer look
Q35929030	B7H6-specific chimeric antigen receptors lead to tumor elimination and host antitumor immunity
Q37531026	BCR/ABL can promote CD19+ cell growth but not render them long-term stemness
Q47389306	BRAF peptide vaccine facilitates therapy of murine BRAF-mutant melanoma.
Q61796555	Baboon envelope LVs efficiently transduced human adult, fetal, and progenitor T cells and corrected SCID-X1 T-cell deficiency
Q34380489	Back to the future! The evolving role of maintenance therapy after hematopoietic stem cell transplantation.
Q89578028	Beyond Tumor Suppression: Senescence in Cancer Stemness and Tumor Dormancy
Q38370539	Beyond consolidation: auto-SCT and immunotherapy for plasma cell myeloma.
Q41830617	Beyond the antigen receptor: editing the genome of T-cells for cancer adoptive cellular therapies.
Q55258810	Bibliometric Analysis of Tumor Immunotherapy Studies.
Q63246717	BioBits™ Bright: A fluorescent synthetic biology education kit
Q38262688	Bioinformatics for cancer immunotherapy target discovery
Q33907565	Biology and clinical application of CAR T cells for B cell malignancies
Q61954919	Biomanufacturing for clinically advanced cell therapies
Q37919589	Biomarkers in T cell therapy clinical trials
Q49878390	Biomarkers of cytokine release syndrome and neurotoxicity related to CAR-T cell therapy.
Q30519567	Biophysical mechanism of T-cell receptor triggering in a reconstituted system
Q36456512	Bioreactors get personal
Q35989308	Biosensors for immune cell analysis-A perspective
Q91634144	Bispecific Antibodies in the Treatment of Hematologic Malignancies
Q36659270	Bispecific T-cells expressing polyclonal repertoire of endogenous γδ T-cell receptors and introduced CD19-specific chimeric antigen receptor
Q34517676	Bispecific antibodies and CARs: generalized immunotherapeutics harnessing T cell redirection
Q37378009	Blinatumomab induces autologous T-cell killing of chronic lymphocytic leukemia cells
Q38799449	Blinatumomab: a CD19/CD3 bispecific T cell engager (BiTE) with unique anti-tumor efficacy
Q26785828	Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia
Q89777599	Blockade of CD7 expression in T cells for effective chimeric antigen receptor targeting of T-cell malignancies
Q42683483	Blockade of PD-1 immunosuppression boosts CAR T-cell therapy
Q35591760	Blood and marrow transplant clinical trials network state of the Science Symposium 2014
Q42428460	Blood's 70th anniversary: CARs on the Blood highway.
Q27022883	Bone specific immunity and its impact on metastasis
Q38708600	Breakthrough therapies in B-cell non-Hodgkin lymphoma.
Q38994975	Broad T-cell receptor repertoire in T-lymphocytes derived from human induced pluripotent stem cells
Q52369234	Building a CAR Garage: Preparing for the Delivery of Commercial CAR T Cell Products at Memorial Sloan Kettering Cancer Center.
Q47443955	Building a Safer and Faster CAR: Seatbelts, Airbags, and CRISPR.
Q90677062	CAR T Cell Therapy Progress and Challenges for Solid Tumors
Q99730742	CAR T Cell Therapy for Solid Tumors: Bright Future or Dark Reality?
Q38813257	CAR T Cell Therapy in Acute Lymphoblastic Leukemia and Potential for Chronic Lymphocytic Leukemia
Q60047537	CAR T Cell Therapy of Non-hematopoietic Malignancies: Detours on the Road to Clinical Success
Q26822769	CAR T Cell Therapy: A Game Changer in Cancer Treatment
Q91868621	CAR T Cells Beyond Cancer: Hope for Immunomodulatory Therapy of Infectious Diseases
Q64891859	CAR T Cells in Solid Tumors: Blueprints for Building Effective Therapies.
Q56966447	CAR T Cells with Enhanced Sensitivity to B Cell Maturation Antigen for the Targeting of B Cell Non-Hodgkin's Lymphoma and Multiple Myeloma
Q55382852	CAR T cell therapy for breast cancer: harnessing the tumor milieu to drive T cell activation.
Q90475786	CAR T cells for infection, autoimmunity and allotransplantation
Q26825489	CAR T cells for solid tumors: armed and ready to go?
Q92325228	CAR T cells take centre stage
Q90066105	CAR T cells: continuation in a revolution of immunotherapy
Q26800814	CAR T-Cell Therapy: The Role of Physical Barriers and Immunosuppression in Lymphoma
Q38632105	CAR T-cell immunotherapy: The path from the by-road to the freeway?
Q64115851	CAR T-cell therapy for B-cell lymphomas: clinical trial results of available products
Q57291659	CAR T-cell therapy for glioblastoma: recent clinical advances and future challenges
Q39047856	CAR T-cell therapy of solid tumors.
Q90705235	CAR Talk: How Cancer-Specific CAR T Cells Can Instruct How to Build CAR T Cells to Cure HIV
Q75720015	CAR exosomes derived from effector CAR-T cells have potent antitumour effects and low toxicity
Q41845446	CAR's made it to the pancreas
Q35834087	CAR-Engineered NK Cells Targeting Wild-Type EGFR and EGFRvIII Enhance Killing of Glioblastoma and Patient-Derived Glioblastoma Stem Cells.
Q37022738	CAR-T Cell Therapies From the Transfusion Medicine Perspective
Q36519358	CAR-T Cell Therapy for Lymphoma.
Q59809431	CAR-T Cell Therapy: A Door Is Open to Find Innumerable Possibilities of Treatments for Cancer Patients
Q49722635	CAR-T Cells: A Systematic Review and Mixed Methods Analysis of the Clinical Trial Landscape.
Q50033603	CAR-T cell manufacturing: time to put it in gear.
Q42362802	CAR-T cell therapy in ovarian cancer: from the bench to the bedside
Q90751917	CAR-T cell therapy: a potential new strategy against prostate cancer
Q46018826	CAR-T cells and allogeneic hematopoietic stem cell transplantation for relapsed/refractory B-cell acute lymphoblastic leukemia.
Q36256299	CAR-T cells are serial killers
Q39010819	CAR-T therapy for leukemia: progress and challenges
Q34044213	CAR-modified T-cell therapy for cancer: an updated review.
Q38164792	CAR-modified anti-CD19 T cells for the treatment of B-cell malignancies: rules of the road
Q58606449	CART Immunotherapy: Development, Success, and Translation to Malignant Gliomas and Other Solid Tumors
Q42421978	CARs Move To the Fast Lane.
Q26830526	CARs in chronic lymphocytic leukemia -- ready to drive
Q39246685	CARs: Synthetic Immunoreceptors for Cancer Therapy and Beyond
Q41925285	CD123 AML targeting by chimeric antigen receptors: A novel magic bullet for AML therapeutics?
Q37153598	CD19 CAR immune pressure induces B-precursor acute lymphoblastic leukaemia lineage switch exposing inherent leukaemic plasticity
Q55193924	CD19 CAR-T cell therapy for relapsed/refractory acute lymphoblastic leukemia: factors affecting toxicities and long-term efficacies.
Q36951727	CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients
Q34667972	CD19 CAR-targeted T cells induce long-term remission and B Cell Aplasia in an immunocompetent mouse model of B cell acute lymphoblastic leukemia.
Q33655754	CD19 Isoforms Enabling Resistance to CART-19 Immunotherapy Are Expressed in B-ALL Patients at Initial Diagnosis
Q27011836	CD19 as an attractive target for antibody-based therapy
Q26749139	CD19 chimeric antigen receptor (CD19 CAR)-redirected adoptive T-cell immunotherapy for the treatment of relapsed or refractory B-cell Non-Hodgkin's Lymphomas
Q38370975	CD19 chimeric antigen receptor T cell therapy for haematological malignancies
Q53351994	CD19 expression in acute leukemia is not restricted to the cytogenetically aberrant populations.
Q39122928	CD19 target-engineered T-cells accumulate at tumor lesions in human B-cell lymphoma xenograft mouse models
Q38783833	CD19-CAR engineered NK-92 cells are sufficient to overcome NK cell resistance in B-cell malignancies
Q37692134	CD19-CAR trials
Q28081600	CD19-Chimeric Antigen Receptor T Cells for Treatment of Chronic Lymphocytic Leukaemia and Acute Lymphoblastic Leukaemia
Q39032901	CD19-Targeted CAR T cells as novel cancer immunotherapy for relapsed or refractory B-cell acute lymphoblastic leukemia
Q38832599	CD19-Targeted chimeric antigen receptor-modified T-cell immunotherapy for B-cell malignancies
Q29620607	CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia
Q28084879	CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia
Q92039571	CD19-targeting CAR T cell immunotherapy outcomes correlate with genomic modification by vector integration
Q38371387	CD19: A multifunctional immunological target molecule and its implications for Blineage acute lymphoblastic leukemia
Q38064963	CD19: a biomarker for B cell development, lymphoma diagnosis and therapy
Q35953372	CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results
Q37224921	CD20-targeted T cells after stem cell transplantation for high risk and refractory non-Hodgkin's lymphoma
Q45870963	CD28 and 41BB Costimulation Enhances the Effector Function of CD19-Specific Engager T Cells
Q36279306	CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia
Q39081204	CD3ζ-based chimeric antigen receptors mediate T cell activation via cis- and trans-signalling mechanisms: implications for optimization of receptor structure for adoptive cell therapy
Q27022957	CD4 T-cell immunotherapy for chronic viral infections and cancer
Q36951719	CD62L+ NKT cells have prolonged persistence and antitumor activity in vivo
Q35655089	CD8(+) T cell response to adenovirus vaccination and subsequent suppression of tumor growth: modeling, simulation and analysis
Q42586718	CIMT 2014: Next waves in cancer immunotherapy--report on the 12th annual meeting of the Association for Cancer Immunotherapy: May 6–8 2014, Mainz, Germany
Q45783720	CLL/SLL diagnosed in an adolescent
Q37666309	CS1-specific chimeric antigen receptor (CAR)-engineered natural killer cells enhance in vitro and in vivo antitumor activity against human multiple myeloma
Q93133450	CXCR1- or CXCR2-modified CAR T cells co-opt IL-8 for maximal antitumor efficacy in solid tumors
Q39027714	Can we make a better match or mismatch with KIR genotyping?
Q58080400	Cancer Diagnosis and Immunotherapy in the age of CRISPR
Q64987872	Cancer Immunotherapy Based on Natural Killer Cells: Current Progress and New Opportunities.
Q38283536	Cancer Immunotherapy Using γδT Cells: Dealing with Diversity
Q56889030	Cancer Immunotherapy in Diffuse Large B-Cell Lymphoma
Q38616707	Cancer Immunotherapy: Historical Perspective of a Clinical Revolution and Emerging Preclinical Animal Models
Q38737924	Cancer Immunotherapy: Whence and Whither
Q59133785	Cancer Vaccine Immunotherapy with RNA-Loaded Liposomes
Q91740150	Cancer biomarkers for targeted therapy
Q37655422	Cancer cell-oriented migration of mesenchymal stem cells engineered with an anticancer gene (PTEN): an imaging demonstration.
Q38106230	Cancer immunotherapies, their safety and toxicity.
Q27026870	Cancer immunotherapy
Q29619918	Cancer immunotherapy comes of age
Q34309399	Cancer immunotherapy in clinical practice -- the past, present, and future.
Q36387028	Cancer immunotherapy: Strategies for personalization and combinatorial approaches
Q38151738	Cancer immunotherapy: accomplishments to date and future promise
Q39297560	Cancer immunotherapy: are we there yet?
Q36637039	Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy
Q97546137	Cancer systems immunology
Q26782604	Cancer-treatment-induced neurotoxicity--focus on newer treatments
Q52592605	Cardiotoxicity of Immunotherapy: Incidence, Diagnosis, and Management.
Q37095348	Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma.
Q36757071	Case Report of a Fatal Serious Adverse Event Upon Administration of T Cells Transduced With a MART-1-specific T-cell Receptor
Q91933415	Caveolin-2 deficiency induces a rapid anti-tumor immune response prior to regression of implanted murine lung carcinoma tumors
Q92970937	Cell Adhesion Molecules and Their Roles and Regulation in the Immune and Tumor Microenvironment
Q47738496	Cell Membrane Bioconjugation and Membrane-Derived Nanomaterials for Immunotherapy.
Q38794293	Cell and gene therapy strategies to eradicate HIV reservoirs
Q55887721	Cell therapy fights leukaemia
Q38777005	Cell-Mediated Immunity to Target the Persistent Human Immunodeficiency Virus Reservoir
Q36984482	Cell-based immunotherapy against gliomas: from bench to bedside
Q90288095	Cell-based immunotherapy approaches for multiple myeloma
Q38219579	Cell-based strategies to manage leukemia relapse: efficacy and feasibility of immunotherapy approaches
Q42613853	Cell-based therapeutics: the next pillar of medicine
Q36261159	Cellular and Antibody Based Approaches for Pediatric Cancer Immunotherapy
Q36801106	Cellular immunotherapy for carcinoma using genetically modified EGFR-specific T lymphocytes
Q27014912	Cellular immunotherapy for pediatric solid tumors
Q38104288	Cellular immunotherapy for plasma cell myeloma.
Q38217594	Cellular immunotherapy strategies for Ewing sarcoma
Q47764871	Cellular kinetics of CTL019 in relapsed/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia
Q36552098	Cellular therapies in acute lymphoblastic leukemia
Q52569021	Cellular therapies: Day by day, all the way.
Q45875669	Cellular therapy for cancer: let there be light
Q35843507	Challenges and future perspectives of T cell immunotherapy in cancer
Q34343785	Challenges and opportunities for international cooperative studies in pediatric hematopoeitic cell transplantation: priorities of the Westhafen Intercontinental Group
Q36257036	Challenges and opportunities of allogeneic donor-derived CAR T cells
Q36372755	Characterization of T-cell receptors directed against HLA-A01-restricted and C07-restricted epitopes of MAGE-A3 and MAGE-A12.
Q55322285	Characterization of a switchable chimeric antigen receptor platform in a pre-clinical solid tumor model.
Q89486119	Characterization of an Anti-CD5 Directed CAR T-Cell against T-Cell Malignancies
Q57482923	Characterization of clinical grade CD19 chimeric antigen receptor T cells produced using automated CliniMACS Prodigy system
Q37308164	Characterization of distinct immunophenotypes across pediatric brain tumor types
Q48562384	Chasing cancer with chimeric antigen receptor therapy.
Q57300937	Checkpoint Blockade Reverses Anergy in IL-13Rα2 Humanized scFv-Based CAR T Cells to Treat Murine and Canine Gliomas
Q38837680	Checkpoint Inhibitors and Other Immune Therapies for Hodgkin and Non-Hodgkin Lymphoma
Q58768316	Chemokine Receptors and Exercise to Tackle the Inadequacy of T Cell Homing to the Tumor Site
Q33792344	Chemokines as Cancer Vaccine Adjuvants.
Q34041792	Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor
Q33783145	Children's Oncology Group's 2013 blueprint for research: stem cell transplantation.
Q37609801	Chimaeric antigen receptor T-cell therapy for tumour immunotherapy
Q53705286	Chimeric Antigen Receptor Expressing Natural Killer Cells for the Immunotherapy of Cancer.
Q52663662	Chimeric Antigen Receptor T Cell Therapy and the Kidney: What the Nephrologist Needs to Know.
Q36722700	Chimeric Antigen Receptor T Cell Therapy in Hematology
Q37347313	Chimeric Antigen Receptor T Cells Guided by the Single-Chain Fv of a Broadly Neutralizing Antibody Specifically and Effectively Eradicate Virus Reactivated from Latency in CD4+ T Lymphocytes Isolated from HIV-1-Infected Individuals Receiving Suppres
Q36284584	Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma
Q38957129	Chimeric Antigen Receptor T Cells and Hematopoietic Cell Transplantation: How Not to Put the CART Before the Horse
Q39082264	Chimeric Antigen Receptor T Cells in Hematologic Malignancies
Q47332598	Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas
Q64957593	Chimeric Antigen Receptor T Cells: A Race to Revolutionize Cancer Therapy.
Q38913549	Chimeric Antigen Receptor T cells for B Cell Neoplasms: Choose the Right CAR for You.
Q36884399	Chimeric Antigen Receptor T-Cell Therapy for the Community Oncologist
Q50531950	Chimeric Antigen Receptor T-Cells for the Treatment of B-Cell Acute Lymphoblastic Leukemia.
Q59137010	Chimeric Antigen Receptor T-Cells: Successful Translation of the First Cell and Gene Therapy From Bench to Bedside
Q89419402	Chimeric Antigen Receptor Therapy
Q39401736	Chimeric Antigen Receptor Therapy in Acute Lymphoblastic Leukemia Clinical Practice
Q26799357	Chimeric Antigen Receptor- and TCR-Modified T Cells Enter Main Street and Wall Street
Q46058008	Chimeric Antigen Receptor-Modified T Cells Redirected to EphA2 for the Immunotherapy of Non-Small Cell Lung Cancer
Q92301970	Chimeric Antigen Receptor-T Cells for Targeting Solid Tumors: Current Challenges and Existing Strategies
Q89895682	Chimeric Antigen Receptor-T-Cell Therapy for B-Cell Hematological Malignancies: An Update of the Pivotal Clinical Trial Data
Q58575867	Chimeric Antigen Receptors Based on Low Affinity Mutants of FcεRI Re-direct T Cell Specificity to Cells Expressing Membrane IgE
Q26773309	Chimeric Antigen Receptors Modified T-Cells for Cancer Therapy
Q38795058	Chimeric Antigen Receptors for Cancer Immunotherapy
Q36720681	Chimeric NKG2D CAR-expressing T cell-mediated attack of human ovarian cancer is enhanced by histone deacetylase inhibition
Q59793960	Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance
Q64054386	Chimeric antigen receptor (CAR) T-cell therapy as a treatment option for patients with B-cell lymphomas: perspectives on the therapeutic potential of Axicabtagene ciloleucel
Q42246628	Chimeric antigen receptor (CAR)-directed adoptive immunotherapy: a new era in targeted cancer therapy
Q36682313	Chimeric antigen receptor (CAR)-engineered T cells redirected against hepatitis C virus (HCV) E2 glycoprotein.
Q38685785	Chimeric antigen receptor (CAR)-modified natural killer cell-based immunotherapy and immunological synapse formation in cancer and HIV.
Q27312288	Chimeric antigen receptor (CAR)-specific monoclonal antibody to detect CD19-specific T cells in clinical trials
Q37436837	Chimeric antigen receptor T Cells with dissociated signaling domains exhibit focused antitumor activity with reduced potential for toxicity in vivo
Q49280922	Chimeric antigen receptor T cell (CAR-T) immunotherapy for solid tumors: lessons learned and strategies for moving forward.
Q52588132	Chimeric antigen receptor T cell therapy for non-Hodgkin lymphoma.
Q38732332	Chimeric antigen receptor T cell treatment in hematologic malignancies
Q85800899	Chimeric antigen receptor T cells for ALL
Q29617588	Chimeric antigen receptor T cells for sustained remissions in leukemia
Q41429394	Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia
Q38600697	Chimeric antigen receptor T-cell therapies for lymphoma
Q47776210	Chimeric antigen receptor T-cell therapies for multiple myeloma
Q47681829	Chimeric antigen receptor T-cell therapy - assessment and management of toxicities.
Q64270990	Chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma: opportunities and challenges
Q39442191	Chimeric antigen receptor T-cells for B-cell malignancies
Q36858767	Chimeric antigen receptor containing ICOS signaling domain mediates specific and efficient antitumor effect of T cells against EGFRvIII expressing glioma
Q39208504	Chimeric antigen receptor engineered stem cells: a novel HIV therapy
Q38435415	Chimeric antigen receptor engineering: a right step in the evolution of adoptive cellular immunotherapy
Q34256494	Chimeric antigen receptor for adoptive immunotherapy of cancer: latest research and future prospects
Q38171402	Chimeric antigen receptor modified T cell therapy for B cell malignancies
Q27013599	Chimeric antigen receptor therapy for cancer
Q38096540	Chimeric antigen receptor therapy for chronic lymphocytic leukemia: what are the challenges?
Q36845643	Chimeric antigen receptor--modified T cells: clinical translation in stem cell transplantation and beyond
Q27025300	Chimeric antigen receptor-engineered T cells for cancer immunotherapy: progress and challenges
Q38873430	Chimeric antigen receptor-engineered T cells for liver cancers, progress and obstacles
Q35980893	Chimeric antigen receptor-engineered T cells for the treatment of metastatic prostate cancer
Q34046190	Chimeric antigen receptor-engineered T cells in CLL: the next chapter unfolds
Q59329883	Chimeric antigen receptor-modified T cell therapy in chronic lymphocytic leukemia
Q34044910	Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo
Q29620130	Chimeric antigen receptor-modified T cells for acute lymphoid leukemia
Q50042810	Chimeric antigen receptor-modified T cells for the immunotherapy of patients with EGFR-expressing advanced relapsed/refractory non-small cell lung cancer.
Q38845812	Chimeric antigen receptor-modified T cells for the treatment of solid tumors: Defining the challenges and next steps
Q37040370	Chimeric antigen receptor-modified T cells strike back
Q34765959	Chimeric antigen receptor-redirected CD45RA-negative T cells have potent antileukemia and pathogen memory response without graft-versus-host activity
Q43575698	Chimeric antigen receptor-redirected T cells display multifunctional capacity and enhanced tumor-specific cytokine secretion upon secondary ligation of chimeric receptor
Q34248531	Chimeric antigen receptors for T cell immunotherapy: current understanding and future directions
Q36386891	Chimeric antigen receptors for the adoptive T cell therapy of hematologic malignancies
Q38987239	Chimeric antigen receptors for treatment of glioblastoma: a practical review of challenges and ways to overcome them
Q50984719	Chimeric antigen receptors: a costimulatory boost promotes immunological memory to B-cell malignancies.
Q47812178	Chimeric switch receptor: switching for improved adoptive T-cell therapy against cancers
Q45832774	Chimeric-antigen receptor T (CAR-T) cell therapy for solid tumors: challenges and opportunities
Q90330460	Chronic Lymphocytic Leukaemia in 2020: the Future Has Arrived
Q87869046	Chronic lymphocytic leukaemia
Q94562886	Chronic lymphocytic leukemia in 2020: a surfeit of riches?
Q38646074	Chronic lymphocytic leukemia: 2017 update on diagnosis, risk stratification, and treatment
Q26752467	Chronic lymphocytic leukemia: a clinical review including Korean cohorts
Q36609259	Chronic lymphocytic leukemia: inception to cure: are we there?
Q35149637	Classification of current anticancer immunotherapies
Q38962267	Clinical Practice Recommendations for Use of Allogeneic Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation
Q34511646	Clinical application of genetically modified T cells in cancer therapy
Q100395396	Clinical development of CAR T cell therapy in China: 2020 update
Q33823270	Clinical development of anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma
Q26743393	Clinical development of gene therapy: results and lessons from recent successes
Q38668561	Clinical development of immunotherapy for prostate cancer
Q26747037	Clinical manufacturing of CAR T cells: foundation of a promising therapy
Q52774309	Clinical methods of cryopreservation for donor lymphocyte infusions vary in their ability to preserve functional T-cell subpopulations.
Q38195338	Clinical potential of gene therapy: towards meeting the demand
Q37042225	Clinical responses with T lymphocytes targeting malignancy-associated κ light chains
Q38105123	Clinical significance of minimal residual disease in patients with acute leukaemia undergoing haematopoietic stem cell transplantation
Q36762882	Clinical targeting of the TNF and TNFR superfamilies
Q61797408	Clinical trial update on bispecific antibodies, antibody-drug conjugates, and antibody-containing regimens for acute lymphoblastic leukemia
Q38094811	Clinical trials in cellular immunotherapy for brain/CNS tumors
Q42654456	Clinical trials of CAR-T cells in China
Q50041712	Clinical trials of CD19-targeted CAR-modified T cell therapy; a complex and varied landscape.
Q64005145	Clinical trials of dual-target CAR T cells, donor-derived CAR T cells, and universal CAR T cells for acute lymphoid leukemia
Q38195120	Clinical utility of natural killer cells in cancer therapy and transplantation
Q39177978	Clinical-scale derivation of natural killer cells from human pluripotent stem cells for cancer therapy.
Q42280014	Clinical-scale selection and viral transduction of human naïve and central memory CD8+ T cells for adoptive cell therapy of cancer patients.
Q88763304	Clinically Relevant Cytotoxic Immune Cell Signatures and Clonal Expansion of T-Cell Receptors in High-Risk MYCN-Not-Amplified Human Neuroblastoma
Q52655396	Clinically compliant spatial and temporal imaging of chimeric antigen receptor T-cells.
Q33749635	Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15
Q38811497	Coexpressed Catalase Protects Chimeric Antigen Receptor-Redirected T Cells as well as Bystander Cells from Oxidative Stress-Induced Loss of Antitumor Activity.
Q34487698	Combination cancer immunotherapy and new immunomodulatory targets
Q36018407	Combination immunotherapy after ASCT for multiple myeloma using MAGE-A3/Poly-ICLC immunizations followed by adoptive transfer of vaccine-primed and costimulated autologous T cells
Q34552128	Combination immunotherapy: a road map.
Q39111239	Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma.
Q91947120	Combined Antitumor Effects of Sorafenib and GPC3-CAR T Cells in Mouse Models of Hepatocellular Carcinoma
Q40427938	Combining Cell and Gene Therapy in an Effort to Eradicate HIV.
Q37443603	Combining T-cell immunotherapy and anti-androgen therapy for prostate cancer
Q28537688	Combining a CD20 chimeric antigen receptor and an inducible caspase 9 suicide switch to improve the efficacy and safety of T cell adoptive immunotherapy for lymphoma
Q38447992	Combining immunotherapy and anticancer agents: the right path to achieve cancer cure?
Q35196739	Common Ewing sarcoma-associated antigens fail to induce natural T cell responses in both patients and healthy individuals
Q47570358	Comparison of T Cell Activities Mediated by Human TCRs and CARs That Use the Same Recognition Domains
Q39408105	Comparison of different suicide-gene strategies for the safety improvement of genetically manipulated T cells.
Q34808631	Comparison of lentiviral and sleeping beauty mediated αβ T cell receptor gene transfer
Q36377047	Comparison of mRNA and lentiviral based transfection of natural killer cells with chimeric antigen receptors recognizing lymphoid antigens
Q37127489	Complete TCR-α gene locus control region activity in T cells derived in vitro from embryonic stem cells
Q35563824	Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells.
Q37129564	Complete remission after single agent blinatumomab in a patient with pre-B acute lymphoid leukemia relapsed and refractory to three prior regimens: hyperCVAD, high dose cytarabine mitoxantrone and CLAG.
Q40183378	Comprehensive Approach for Identifying the T Cell Subset Origin of CD3 and CD28 Antibody-Activated Chimeric Antigen Receptor-Modified T Cells
Q50914423	Conference scene: Immune signatures in the tumor and beyond.
Q45870279	Considerations in T Cell Therapy Product Development for B Cell Leukemia and Lymphoma Immunotherapy
Q36963057	Construction of a new anti-CD19 chimeric antigen receptor and the anti-leukemia function study of the transduced T cells
Q41437137	Construction of stable packaging cell lines for clinical lentiviral vector production
Q35149457	Control of established colon cancer xenografts using a novel humanized single chain antibody-streptococcal superantigen fusion protein targeting the 5T4 oncofetal antigen.
Q89793732	Controlling Cytokine Release Syndrome to Harness the Full Potential of CAR-Based Cellular Therapy
Q36349583	Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy
Q38064950	Convergence of gene and cell therapy
Q47821811	Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity.
Q50936078	Cord blood T cells retain early differentiation phenotype suitable for immunotherapy after TCR gene transfer to confer EBV specificity.
Q55262180	Crisis or self-correction: Rethinking media narratives about the well-being of science.
Q38085989	Curing HIV: lessons from cancer therapy
Q38830071	Current Progress in Immunotherapy for the Treatment of Biliary Cancers
Q92662855	Current Status and Future Perspectives of Immunotherapy for Locally Advanced or Metastatic Urothelial Carcinoma: A Comprehensive Review
Q49829282	Current Status of Gene Engineering Cell Therapeutics.
Q35215158	Current advances in T-cell-based cancer immunotherapy
Q26745411	Current clinical immunotherapeutic approaches for head and neck cancer
Q33886879	Current concepts in the diagnosis and management of cytokine release syndrome
Q39189908	Current modalities in cancer immunotherapy: Immunomodulatory antibodies, CARs and vaccines
Q26799720	Current practices and reform proposals for the regulation of advanced medicinal products in Canada
Q39280002	Current status and perspectives of chimeric antigen receptor modified T cells for cancer treatment
Q49504358	Current status and progress of lymphoma management in China.
Q39301512	Current status of chimeric antigen receptor engineered T cell-based and immune checkpoint blockade-based cancer immunotherapies
Q38631108	Current status of chimeric antigen receptor therapy for haematological malignancies
Q55715408	Current status of immunotherapy against gastrointestinal cancers and its biomarkers: Perspective for precision immunotherapy.
Q38068967	Current strategies in immunotherapy for acute myeloid leukemia
Q50027576	Current strategies to improve the safety of chimeric antigen receptor (CAR) modified T cells.
Q38164108	Current therapy and novel agents for relapsed or refractory acute lymphoblastic leukemia
Q27024456	Current translational and clinical practices in hematopoietic cell and gene therapy
Q36397924	Cytogenetic prioritization with inclusion of molecular markers predicts outcome in previously untreated patients with chronic lymphocytic leukemia treated with fludarabine or fludarabine plus cyclophosphamide: a long-term follow-up study of the US i
Q95648221	Cytokine IL-36γ improves CAR T-cell functionality and induces endogenous antitumor response
Q39385892	Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy for Acute Lymphoblastic Leukemia.
Q40247636	Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy.
Q55438228	Cytokine release syndrome.
Q58700983	Cytokine release syndrome: grading, modeling, and new therapy
Q89613154	Cytotoxic CD8+ Lymphocytes in the Tumor Microenvironment
Q36694195	Cytotoxic T cells induce proliferation of chronic myeloid leukemia stem cells by secreting interferon-γ.
Q37991701	Cytotoxic chemotherapy and CD4+ effector T cells: an emerging alliance for durable antitumor effects
Q37222769	DNA aptamer-mediated cell targeting
Q38948889	DNA-based immunotherapy for HPV-associated head and neck cancer
Q35209066	DNAM-1-based chimeric antigen receptors enhance T cell effector function and exhibit in vivo efficacy against melanoma
Q92354573	Decitabine enhances cytotoxic effect of T cells with an anti-CD19 chimeric antigen receptor in treatment of lymphoma
Q88573546	Defining success with cellular therapeutics: the current landscape for clinical end point and toxicity analysis
Q39320917	Definition and application of good manufacturing process-compliant production of CEA-specific chimeric antigen receptor expressing T-cells for phase I/II clinical trial.
Q37420778	Dendritic cell-based immunotherapy for myeloid leukemias.
Q47547004	Desensitized chimeric antigen receptor T cells selectively recognize target cells with enhanced antigen expression.
Q89633817	Design and Characterization of an "All-in-One" Lentiviral Vector System Combining Constitutive Anti-GD2 CAR Expression and Inducible Cytokines
Q51851755	Design and Potential of Non-Integrating Lentiviral Vectors.
Q37418289	Design and development of therapies using chimeric antigen receptor-expressing T cells
Q38170500	Design and implementation of adoptive therapy with chimeric antigen receptor-modified T cells
Q34439729	Design of T-cell receptor libraries with diverse binding properties to examine adoptive T-cell responses
Q38805082	Design of chimeric antigen receptors with integrated controllable transient functions.
Q41964506	Designing CAR T cells for glioblastoma
Q88955690	Designing cell function: assembly of synthetic gene circuits for cell biology applications
Q38260051	Designing effective vaccines for colorectal cancer.
Q36100435	Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia
Q38003108	Detection of EPO gene doping in blood
Q26996310	Developing strategies in the immunotherapy of leukemias
Q28730144	Development and utility of an internal threshold control (ITC) real-time PCR assay for exogenous DNA detection
Q28067476	Development of Auto Antigen-specific Regulatory T Cells for Diabetes Immunotherapy
Q39200527	Development of CAR T cells designed to improve antitumor efficacy and safety
Q58614180	Development of Inducible CD19-CAR T Cells with a Tet-On System for Controlled Activity and Enhanced Clinical Safety
Q52365121	Development of Molecularly Targeted Agents and Immunotherapies in Glioblastoma: A Personalized Approach.
Q50035377	Development of T cells carrying two complementary chimeric antigen receptors against glypican-3 and asialoglycoprotein receptor 1 for the treatment of hepatocellular carcinoma.
Q41820949	Development of a novel universal immune receptor for antigen targeting: To Infinity and beyond
Q38999828	Development of an equine-tropic replication-competent lentivirus assay for equine infectious anemia virus-based lentiviral vectors
Q37132611	Development of gene therapy for blood disorders: an update
Q50885033	Development of immuno-oncology drugs - from CTLA4 to PD1 to the next generations.
Q39391468	Development of novel antigen receptors for CAR T-cell therapy directed toward solid malignancies
Q36820360	Diacylglycerol kinases: regulated controllers of T cell activation, function, and development
Q88947859	Diagnosis and management of pulmonary toxicity associated with cancer immunotherapy
Q38860645	Dielectrophoresis-assisted 3D nanoelectroporation for non-viral cell transfection in adoptive immunotherapy.
Q34297618	Different affinity windows for virus and cancer-specific T-cell receptors: implications for therapeutic strategies
Q54839684	Direct Lymph Node Vaccination of Lentivector/Prostate-Specific Antigen is Safe and Generates Tissue-Specific Responses in Rhesus Macaques.
Q90134023	Direct comparison of target-reactivity and cross-reactivity induced by CAR- and BiTE-redirected T cells for the development of antibody-based T-cell therapy
Q38906557	Disialoganglioside-specific human natural killer cells are effective against drug-resistant neuroblastoma.
Q58889356	Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells
Q36819337	Dissecting graft-versus-leukemia from graft-versus-host-disease using novel strategies
Q37390239	Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation
Q44064028	Double or nothing on cancer immunotherapy
Q34046505	Driving CAR T-cells forward
Q37715684	Driving CAR-based T-cell therapy to success
Q41844141	Driving an improved CAR for cancer immunotherapy
Q38777742	Driving gene-engineered T cell immunotherapy of cancer
Q93048204	Durable Molecular Remission in a Lymphoid BP-CML Patient Harboring T315I Mutation Treated with Anti-CD19 CAR-T Therapy
Q37618652	EGFRvIII mCAR-modified T-cell therapy cures mice with established intracerebral glioma and generates host immunity against tumor-antigen loss.
Q35145144	EGFRvIII-specific chimeric antigen receptor T cells migrate to and kill tumor deposits infiltrating the brain parenchyma in an invasive xenograft model of glioblastoma
Q50681689	Early memory phenotypes drive T cell proliferation in patients with pediatric malignancies.
Q38747333	Effective and persistent antitumor activity of HER2-directed CAR-T cells against gastric cancer cells in vitro and xenotransplanted tumors in vivo
Q39324107	Effector memory and central memory NY-ESO-1-specific re-directed T cells for treatment of multiple myeloma.
Q47187516	Efficacy From Strange Sources
Q38035043	Efficacy and safety of adoptive immunotherapy using anti-CD19 chimeric antigen receptor transduced T-cells: a systematic review of phase I clinical trials
Q47183140	Efficacy and safety of chimeric antigen receptor T-cell (CAR-T) therapy in patients with haematological and solid malignancies: protocol for a systematic review and meta-analysis.
Q29617590	Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia
Q36545348	Efficiency of CD19 chimeric antigen receptor-modified T cells for treatment of B cell malignancies in phase I clinical trials: a meta-analysis
Q38723282	Efficient Transduction of Human and Rhesus Macaque Primary T Cells by a Modified Human Immunodeficiency Virus Type 1-Based Lentiviral Vector
Q35847460	Elevated Cancer-Specific Mortality Among HIV-Infected Patients in the United States
Q33587034	Elimination of progressive mammary cancer by repeated administrations of chimeric antigen receptor-modified T cells
Q30252944	Elutriated lymphocytes for manufacturing chimeric antigen receptor T cells.
Q90479721	Emerging Approaches for Regulation and Control of CAR T Cells: A Mini Review
Q52596335	Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies.
Q88549071	Emerging Systemic Therapies for Colorectal Cancer
Q91776744	Emerging agents and regimens for treatment of relapsed and refractory acute myeloid leukemia
Q38172586	Emerging drugs for acute lymphocytic leukemia
Q38543771	Emerging immunological drugs for chronic lymphocytic leukemia
Q37025105	Emerging immunotherapies for glioblastoma
Q38075407	Emerging immunotherapies in older adults with acute myeloid leukemia
Q38806960	Emerging role of immunotherapy in urothelial carcinoma-Future directions and novel therapies
Q38207143	Emerging therapies for refractory chronic lymphocytic leukemia
Q91994349	Emerging treatment options for patients with p53-pathway-deficient CLL
Q38235439	Emerging trends and new developments in regenerative medicine: a scientometric update (2000 - 2014).
Q56891263	Endocrine, Sexual Function, and Infertility Side Effects of Immune Checkpoint Inhibitor Therapy for Genitourinary Cancers
Q35591391	Engager T cells: a new class of antigen-specific T cells that redirect bystander T cells
Q37711887	Engineered CAR T Cells Targeting the Cancer-Associated Tn-Glycoform of the Membrane Mucin MUC1 Control Adenocarcinoma
Q38623827	Engineered T cell therapies
Q36755385	Engineered T cells for anti-cancer therapy.
Q34080368	Engineered T cells for cancer therapy.
Q33578792	Engineered T cells for cancer treatment
Q55086081	Engineered T cells targeting E7 mediate regression of human papillomavirus cancers in a murine model.
Q38828829	Engineered T cells: the promise and challenges of cancer immunotherapy.
Q52641577	Engineered T lymphocytes eliminate lung metastases in models of pancreatic cancer.
Q85092790	Engineered T-cell therapy shows efficacy in blood cancer
Q36936632	Engineered human embryonic stem cell-derived lymphocytes to study in vivo trafficking and immunotherapy
Q58694793	Engineering CAR-T Cells for Improved Function Against Solid Tumors
Q39399864	Engineering CAR-T cells
Q38290031	Engineering CAR-T cells: Design concepts
Q92488848	Engineering DNA recognition and allosteric response properties of TetR family proteins by using a module-swapping strategy
Q40351372	Engineering HIV-Resistant, Anti-HIV Chimeric Antigen Receptor T Cells
Q38742968	Engineering T Cells with Customized Therapeutic Response Programs Using Synthetic Notch Receptors
Q92150152	Engineering advanced cancer therapies with synthetic biology
Q91847813	Engineering for Success: Approaches to Improve Chimeric Antigen Receptor T Cell Therapy for Solid Tumors
Q90317680	Engineering of an enhanced synthetic Notch receptor by reducing ligand-independent activation
Q92513208	Engineering repressors with coevolutionary cues facilitates toggle switches with a master reset
Q91614877	Engineering switchable and programmable universal CARs for CAR T therapy
Q38231581	Engineering α-fetoprotein-based gene vaccines to prevent and treat hepatocellular carcinoma: review and future prospects
Q102210885	Enhanced CAR-T activity against established tumors by polarizing human T cells to secrete interleukin-9
Q90106278	Enhanced activation and expansion of T cells using mechanically soft elastomer fibers
Q34338159	Enhanced cytotoxicity of natural killer cells following the acquisition of chimeric antigen receptors through trogocytosis
Q36941051	Enhanced effector responses in activated CD8+ T cells deficient in diacylglycerol kinases
Q36882726	Enhancement of the in vivo persistence and antitumor efficacy of CD19 chimeric antigen receptor T cells through the delivery of modified TERT mRNA.
Q50025585	Enhancing CAR T cell persistence through ICOS and 4-1BB costimulation.
Q92306387	Enhancing CAR T-cell therapy through cellular imaging and radiotherapy
Q35399334	Enhancing antitumor efficacy of chimeric antigen receptor T cells through constitutive CD40L expression.
Q50426810	Enhancing cancer immunotherapy through nanotechnology-mediated tumor infiltration and activation of immune cells.
Q89030540	Enhancing the Potency and Specificity of Engineered T Cells for Cancer Treatment
Q38525024	Enhancing the efficacy of adoptive cellular therapy by targeting tumor-induced immunosuppression
Q34172063	Entering the era of targeted therapy for chronic lymphocytic leukemia: impact on the practicing clinician.
Q35252186	Eradicating HIV-1 infection: seeking to clear a persistent pathogen
Q38389298	ErbB-targeted CAR T-cell immunotherapy of cancer
Q92337122	Escape From ALL-CARTaz: Leukemia Immunoediting in the Age of Chimeric Antigen Receptors
Q38769264	Establishing guidelines for CAR-T cells: challenges and considerations
Q36698269	Evaluating risks of insertional mutagenesis by DNA transposons in gene therapy
Q92236859	Evaluating tisagenlecleucel and its potential in the treatment of relapsed or refractory diffuse large B cell lymphoma: evidence to date
Q36675286	Evaluation of TCR Gene Editing Achieved by TALENs, CRISPR/Cas9, and megaTAL Nucleases
Q27006179	Evaluation of current cancer immunotherapy: hemato-oncology
Q54108755	Evolution of CLL treatment - from chemoimmunotherapy to targeted and individualized therapy.
Q59329233	Evolution of Cancer Pharmacological Treatments at the Turn of the Third Millennium
Q45288675	Evolution to plasmablastic lymphoma evades CD19-directed chimeric antigen receptor T cells
Q37081838	Ewing sarcoma dissemination and response to T-cell therapy in mice assessed by whole-body magnetic resonance imaging
Q94559906	Ex vivo blockade of PI3K gamma or delta signaling enhances the antitumor potency of adoptively transferred CD8+ T cells
Q41490849	Ex vivo expansion of human T cells for adoptive immunotherapy using the novel Xeno-free CTS Immune Cell Serum Replacement
Q36715205	Expanding roles for CD4 T cells and their subpopulations in tumor immunity and therapy
Q53369837	Explaining the Paucity of Intratumoral T Cells: A Construction Out of Known Entities.
Q28075992	Exploiting IL-17-producing CD4+ and CD8+ T cells to improve cancer immunotherapy in the clinic
Q37576033	Exploiting the curative potential of adoptive T-cell therapy for cancer
Q93110692	Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma
Q39400633	Expression of IL-15 in NK cells results in rapid enrichment and selective cytotoxicity of gene-modified effectors that carry a tumor-specific antigen receptor
Q49710595	Expression of MAGE-A and NY-ESO-1 cancer-testis antigens is enriched in triple-negative invasive breast cancers.
Q39062014	Expression of a Chimeric Antigen Receptor Specific for Donor HLA Class I Enhances the Potency of Human Regulatory T Cells in Preventing Human Skin Transplant Rejection.
Q38365989	Expression of chimeric receptor CD4ζ by natural killer cells derived from human pluripotent stem cells improves in vitro activity but does not enhance suppression of HIV infection in vivo.
Q91529500	Expression of lymphocyte immunoregulatory biomarkers in bone and soft-tissue sarcomas
Q33606096	Expression of miR-17-92 enhances anti-tumor activity of T-cells transduced with the anti-EGFRvIII chimeric antigen receptor in mice bearing human GBM xenografts
Q36259431	Extracellular Vesicles Present in Human Ovarian Tumor Microenvironments Induce a Phosphatidylserine-Dependent Arrest in the T-cell Signaling Cascade
Q99614559	Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B cell malignancies
Q42552682	False-positive HIV PCR test following ex vivo lentiviral gene transfer treatment of X-linked severe combined immunodeficiency vector
Q54233028	False-positive results with select HIV-1 NAT methods following lentivirus-based tisagenlecleucel therapy.
Q36465536	Faster, cheaper, safer, T-cell engineering
Q47218376	Favorable immune signature in CLL patients, defined by antigen-specific T-cell responses, might prevent second skin cancers
Q38758789	Feasibility and Safety of RNA-transfected CD20-specific Chimeric Antigen Receptor T Cells in Dogs with Spontaneous B Cell Lymphoma.
Q92702413	Finding the Keys to the CAR: Identifying Novel Target Antigens for T Cell Redirection Immunotherapies
Q46112550	Fine-tuning Tumor Immunity with Integrin Trans-regulation
Q40667941	Flow-Through Electroporation of HL-60 White Blood Cell Suspensions using Nanoporous Membrane Electrodes
Q88778743	Fludarabine and neurotoxicity in engineered T-cell therapy
Q38889816	Fluorescence-guided development of a tricistronic vector encoding bimodal optical and nuclear genetic reporters for in vivo cellular imaging
Q47726467	Focused ultrasound for immuno-adjuvant treatment of pancreatic cancer: An emerging clinical paradigm in the era of personalized oncotherapy.
Q35764479	Focusing and sustaining the antitumor CTL effector killer response by agonist anti-CD137 mAb.
Q50635113	Follicle-Stimulating Hormone Receptor Is Expressed by Most Ovarian Cancer Subtypes and Is a Safe and Effective Immunotherapeutic Target.
Q38468283	From humble beginnings to success in the clinic: Chimeric antigen receptor-modified T-cells and implications for immunotherapy.
Q34240799	From the mouse cage to human therapy: a personal perspective of the emergence of T-bodies/chimeric antigen receptor T cells
Q38951943	From therapeutic antibodies to chimeric antigen receptors (CARs): making better CARs based on antigen-binding domain.
Q92715263	Frontline therapies for untreated chronic lymphoid leukemia
Q64230023	Fueling Cancer Immunotherapy With Common Gamma Chain Cytokines
Q36281920	Fully human CD19-specific chimeric antigen receptors for T-cell therapy
Q50027691	Function of Novel Anti-CD19 Chimeric Antigen Receptors with Human Variable Regions Is Affected by Hinge and Transmembrane Domains.
Q60923010	Functional Analysis of an Inducible Promoter Driven by Activation Signals from a Chimeric Antigen Receptor
Q37692713	Functional NK cell repertoires are maintained through IL-2Rα and Fas ligand.
Q36220235	Functional disruption of human leukocyte antigen II in human embryonic stem cell
Q36862410	Functional invariant natural killer T-cell and CD1d axis in chronic lymphocytic leukemia: implications for immunotherapy
Q38434000	Future of Therapy in Acute Lymphoblastic Leukemia (ALL)--Potential Role of Immune-Based Therapies
Q30244168	Future prospects of therapeutic clinical trials in acute myeloid leukemia
Q90482982	GD2 chimeric antigen receptor modified T cells in synergy with sub-toxic level of doxorubicin targeting osteosarcomas
Q38782845	GD2-specific CAR T Cells Undergo Potent Activation and Deletion Following Antigen Encounter but can be Protected From Activation-induced Cell Death by PD-1 Blockade
Q36842259	GIFT4 fusokine converts leukemic B cells into immune helper cells
Q93336074	GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts
Q55353959	GMP-Grade Manufacturing of T Cells Engineered to Express a Defined γδTCR.
Q41625041	GUCY2C-directed CAR-T cells oppose colorectal cancer metastases without autoimmunity
Q37950928	GUCY2C-targeted cancer immunotherapy: past, present and future.
Q52721830	Gene Therapy With Regulatory T Cells: A Beneficial Alliance.
Q35541787	Gene and cell therapy for pancreatic cancer
Q67201058	Gene editing for immune cell therapies
Q37185223	Gene expression profiling using nanostring digital RNA counting to identify potential target antigens for melanoma immunotherapy
Q64041023	Gene therapies advance towards finish line
Q45880394	Gene therapy matures in the clinic
Q27007012	Gene therapy on the move
Q38654544	Gene therapy research in Asia
Q36740288	Gene therapy researchers' assessments of risks and perceptions of risk acceptability in clinical trials
Q33782832	Gene therapy: charting a future course--summary of a National Institutes of Health Workshop, April 12, 2013.
Q92355483	Gene-edited stem cells enable CD33-directed immune therapy for myeloid malignancies
Q38123667	Gene-engineered T cells for cancer therapy
Q101476557	Generation and biobanking of patient-derived glioblastoma organoids and their application in CAR T cell testing
Q91954015	Generation of Antitumor T Cells For Adoptive Cell Therapy With Artificial Antigen Presenting Cells
Q35162266	Generation of CAR T cells for adoptive therapy in the context of glioblastoma standard of care.
Q35651760	Generation of CD19-chimeric antigen receptor modified CD8+ T cells derived from virus-specific central memory T cells
Q38426341	Generation of Potent T-cell Immunotherapy for Cancer Using DAP12-Based, Multichain, Chimeric Immunoreceptors
Q34531834	Generation of functional CLL-specific cord blood CTL using CD40-ligated CLL APC.
Q47438128	Generation of higher affinity T cell receptors by antigen-driven differentiation of progenitor T cells in vitro
Q34487189	Generation of knock-in primary human T cells using Cas9 ribonucleoproteins.
Q52431278	Genetic abrogation of immune checkpoints in antigen-specific cytotoxic T-lymphocyte as a potential alternative to blockade immunotherapy.
Q37965815	Genetic engineering of T cells for the immunotherapy of haematological malignancies.
Q37481319	Genetic engineering of chimeric antigen receptors using lamprey derived variable lymphocyte receptors.
Q33992425	Genetic modification of T cells redirected toward CS1 enhances eradication of myeloma cells
Q36366557	Genetic modification of human T lymphocytes for the treatment of hematologic malignancies
Q34270304	Genetically InFormed therapies--a "GIFT" for children with cancer
Q37587362	Genetically Modified T-Cell-Based Adoptive Immunotherapy in Hematological Malignancies.
Q90862859	Genetically engineered T cells for cancer immunotherapy
Q34645898	Genetically engineered T cells for the treatment of cancer
Q55380614	Genetically enhanced T lymphocytes and the intensive care unit.
Q26860657	Genetically modified T cells for the treatment of malignant disease
Q27026627	Genetically modified T cells in cancer therapy: opportunities and challenges
Q37164976	Genetically modified T cells targeting neovasculature efficiently destroy tumor blood vessels, shrink established solid tumors and increase nanoparticle delivery
Q38178690	Genetically modified T cells to target glioblastoma
Q36198232	Genetically modified T-cell therapy for osteosarcoma
Q33729598	Genome-Edited T Cell Therapies.
Q28087672	Genomic and epigenomic heterogeneity in chronic lymphocytic leukemia
Q44404784	Genomics and drug discovery
Q55358019	Glioblastoma-targeted CD4+ CAR T cells mediate superior antitumor activity.
Q37717884	Global Manufacturing of CAR T Cell Therapy
Q38289029	Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies
Q52729230	Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel.
Q91905271	Granulocyte-macrophage colony-stimulating factor inactivation in CAR T-cells prevents monocyte-dependent release of key cytokine release syndrome mediators
Q39120155	Guanylate cyclase C as a target for prevention, detection, and therapy in colorectal cancer
Q52691583	Gut microbiota modulates adoptive cell therapy via CD8α dendritic cells and IL-12.
Q92472960	HITM-SIR: phase Ib trial of intraarterial chimeric antigen receptor T-cell therapy and selective internal radiation therapy for CEA+ liver metastases
Q88312666	HLA ligandome analysis of primary chronic lymphocytic leukemia (CLL) cells under lenalidomide treatment confirms the suitability of lenalidomide for combination with T-cell-based immunotherapy
Q34204696	HSV-sr39TK positron emission tomography and suicide gene elimination of human hematopoietic stem cells and their progeny in humanized mice
Q35880618	Haematological malignancies: at the forefront of immunotherapeutic innovation
Q35645932	Harnessing autophagy for adoptive T-cell therapy
Q37043025	Harnessing autophagy for cell fate control gene therapy
Q27021570	Harnessing immunosurveillance: current developments and future directions in cancer immunotherapy
Q92156519	Harnessing the Effects of BTKi on T Cells for Effective Immunotherapy against CLL
Q28088598	Harnessing the Microbiome to Enhance Cancer Immunotherapy
Q36416452	Hematopoietic stem cell transplantation for chronic lymphocytic leukemia
Q34463419	Hematopoietic stem cell transplantation-50 years of evolution and future perspectives
Q37512048	Hematopoietic stem cells for cancer immunotherapy
Q39398719	Hemophilia A inhibitor treatment: the promise of engineered T-cell therapy
Q52775663	Heterodimeric IL15 Treatment Enhances Tumor Infiltration, Persistence, and Effector Functions of Adoptively Transferred Tumor-specific T Cells in the Absence of Lymphodepletion.
Q50032893	High efficacy and safety of low-dose CD19-directed CAR-T cell therapy in 51 refractory or relapsed B acute lymphoblastic leukemia patients.
Q64956892	High-Throughput Microfluidic 3D Cytotoxicity Assay for Cancer Immunotherapy (CACI-IMPACT Platform).
Q28066792	High-content molecular profiling of T-cell therapy in oncology
Q94024228	Highlights from the Literature
Q46507832	Highlights of the society for immunotherapy of cancer (SITC) 27th annual meeting
Q91344495	Highly efficient multiplex human T cell engineering without double-strand breaks using Cas9 base editors
Q38830813	How Chimeric Antigen Receptor Design Affects Adoptive T Cell Therapy
Q54348577	How I treat patients with relapsed chronic lymphocytic leukaemia.
Q88645380	How and when I do allogeneic transplant in CLL
Q36476104	How do CARs work?: Early insights from recent clinical studies targeting CD19.
Q38371637	How do i participate in T-cell immunotherapy?
Q92675406	How to approach CLL in clinical practice
Q41660817	Human CD3+ T-Cells with the Anti-ERBB2 Chimeric Antigen Receptor Exhibit Efficient Targeting and Induce Apoptosis in ERBB2 Overexpressing Breast Cancer Cells
Q35598804	Human Epidermal Growth Factor Receptor 2 (HER2) -Specific Chimeric Antigen Receptor-Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma
Q34391263	Human cell-based artificial antigen-presenting cells for cancer immunotherapy
Q98906910	Human immunology and immunotherapy: main achievements and challenges
Q37066334	Human miR223 promoter as a novel myelo-specific promoter for chronic granulomatous disease gene therapy
Q35939496	Human tumor xenografts: the good, the bad, and the ugly
Q38769271	Hurdles of CAR-T cell-based cancer immunotherapy directed against solid tumors
Q64974799	Hypoxia Selectively Impairs CAR-T Cells In Vitro.
Q34047847	ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells
Q35690979	IGF1R- and ROR1-Specific CAR T Cells as a Potential Therapy for High Risk Sarcomas.
Q36651344	Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia
Q27026912	Ibrutinib: a first in class covalent inhibitor of Bruton's tyrosine kinase
Q35689938	Identification and selective expansion of functionally superior T cells expressing chimeric antigen receptors
Q33738328	Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia
Q36470331	Identification of cell surface proteins as potential immunotherapy targets in 12 pediatric cancers
Q35328354	Identification of chimeric antigen receptors that mediate constitutive or inducible proliferation of T cells
Q42287234	Identification of human leucocyte antigen (HLA)-A*0201-restricted cytotoxic T lymphocyte epitopes derived from HLA-DOβ as a novel target for multiple myeloma
Q27334215	Identification of the genomic insertion site of Pmel-1 TCR α and β transgenes by next-generation sequencing
Q91693969	Imaging CAR T cell therapy with PSMA-targeted positron emission tomography
Q53191013	Imaging of T cells expressing chimeric antigen receptors.
Q26796307	Immune Modulation in Hematologic Malignancies
Q38108353	Immune checkpoint blockade immunotherapy to activate anti-tumour T-cell immunity
Q38806038	Immune checkpoint inhibitors in gynecologic cancers with lessons learned from non-gynecologic cancers
Q33691970	Immune escape from NY-ESO-1-specific T-cell therapy via loss of heterozygosity in the MHC.
Q38111096	Immune modulation by genetic modification of dendritic cells with lentiviral vectors.
Q26865561	Immune reconstitution in chronic lymphocytic leukemia
Q39057617	Immune targets and neoantigens for cancer immunotherapy and precision medicine
Q38263108	Immune-based therapies for childhood cancer.
Q45933560	Immuno-oncology Trial Endpoints: Capturing Clinically Meaningful Activity.
Q26765115	Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials
Q37047061	Immunoediting and antigen loss: overcoming the achilles heel of immunotherapy with antigen non-specific therapies
Q37535106	Immunological Outcome in Haploidentical-HSC Transplanted Patients Treated with IL-10-Anergized Donor T Cells
Q37417622	Immunological quality and performance of tumor vessel-targeting CAR-T cells prepared by mRNA-EP for clinical research
Q43884851	Immunology. Making macrophages eat cancer
Q52346985	Immunomodulation in hepatocellular cancer.
Q40829702	Immunosurveillance by antiangiogenesis: tumor growth arrest by T cell-derived thrombospondin-1.
Q36778827	Immunotherapeutic approaches in triple-negative breast cancer: latest research and clinical prospects
Q38171067	Immunotherapeutic approaches to treat multiple myeloma
Q38890717	Immunotherapeutic strategies targeting natural killer T cell responses in cancer.
Q91904998	Immunotherapies for pediatric cancer: current landscape and future perspectives
Q55362851	Immunotherapies: Exploiting the Immune System for Cancer Treatment.
Q49995864	Immunotherapy Strategies Against Multiple Myeloma.
Q90609334	Immunotherapy and Radiation - A New Combined Treatment Approach for Bladder Cancer?
Q38610306	Immunotherapy and tumor microenvironment
Q39016790	Immunotherapy approaches in the treatment of malignant brain tumors
Q42427577	Immunotherapy for B-Cell Neoplasms using T Cells expressing Chimeric Antigen Receptors: From antigen choice to clinical implementation.
Q52587066	Immunotherapy for Breast Cancer: Current and Future Strategies.
Q38580545	Immunotherapy for Multiple Myeloma, Past, Present, and Future: Monoclonal Antibodies, Vaccines, and Cellular Therapies
Q38155343	Immunotherapy for chronic lymphocytic leukemia in the era of BTK inhibitors
Q26745428	Immunotherapy for head and neck cancer: latest developments and clinical potential
Q35567765	Immunotherapy for hepatocellular carcinoma: From basic research to clinical use.
Q38722325	Immunotherapy for pancreatic cancer
Q36968163	Immunotherapy for pediatric leukemia
Q38959645	Immunotherapy for prostate cancer: False promises or true hope?
Q33709232	Immunotherapy for solid tumors--a review for surgeons
Q38533606	Immunotherapy in acute myeloid leukemia
Q33593865	Immunotherapy in hematologic malignancies: past, present, and future
Q36691818	Immunotherapy in pediatric malignancies: current status and future perspectives
Q40099075	Immunotherapy of cancers comes of age.
Q39253341	Immunotherapy of hepatocellular carcinoma using chimeric antigen receptors and bispecific antibodies
Q36470354	Immunotherapy of malignant disease using chimeric antigen receptor engrafted T cells
Q56897379	Immunotherapy of melanoma
Q41259289	Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells
Q27021939	Immunotherapy strategies for multiple myeloma: the present and the future
Q35971029	Immunotherapy targets in pediatric cancer
Q55216327	Immunotherapy with CAR-Modified T Cells: Toxicities and Overcoming Strategies.
Q38117268	Immunotherapy with gene-modified T cells: limiting side effects provides new challenges.
Q37690444	Immunotherapy-induced CD8+ T cells instigate immune suppression in the tumor.
Q50049352	Immunotherapy: Treatment of aggressive lymphomas with anti-CD19 CAR T cells.
Q58326921	Immunothérapie des cancers : une lueur au bout du tunnel ?
Q42265908	Impact of T cell selection methods in the success of clinical adoptive immunotherapy
Q38398877	Impact of the immune system and immunotherapy in colorectal cancer
Q42281477	Impact of the prolymphangiogenic crosstalk in the tumor microenvironment on lymphatic cancer metastasis.
Q52568132	Improved Expansion and In Vivo Function of Patient T Cells by a Serum-free Medium.
Q41879726	Improved anti-leukemia activities of adoptively transferred T cells expressing bispecific T-cell engager in mice
Q40933832	Improved disease markers suggest dual response in a patient with metastatic castration resistant prostate cancer and chronic lymphocytic leukemia following active cellular immunotherapy
Q28068378	Improving Adoptive T Cell Therapy: The Particular Role of T Cell Costimulation, Cytokines, and Post-Transfer Vaccination
Q59349994	Improving CART-Cell Therapy of Solid Tumors with Oncolytic Virus-Driven Production of a Bispecific T-cell Engager
Q38719148	Improving Chimeric Antigen Receptor-Modified T Cell Function by Reversing the Immunosuppressive Tumor Microenvironment of Pancreatic Cancer
Q50051034	Improving immune-vascular crosstalk for cancer immunotherapy.
Q36238795	Improving the outcome for children with cancer: Development of targeted new agents
Q41914105	Improving the outcome of adoptive cell transfer by targeting tumor escape
Q38912826	Improving the safety of T-Cell therapies using an inducible caspase-9 gene
Q34453846	Improving the safety of cell therapy products by suicide gene transfer
Q34477411	Improving the safety of cell therapy with the TK-suicide gene
Q36777093	Improving therapy of chronic lymphocytic leukemia with chimeric antigen receptor T cells
Q53791668	In Vitro Generation of Antigen-Specific T Cells from Induced Pluripotent Stem Cells of Antigen-Specific T Cell Origin.
Q57493527	In Vivo Fate and Activity of Second- versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkin's Lymphomas
Q39087734	In vitro generation of mature, naive antigen-specific CD8(+) T cells with a single T-cell receptor by agonist selection
Q21559398	In vivo suppression of HIV by antigen specific T cells derived from engineered hematopoietic stem cells
Q52780147	In-depth immunophenotyping of patients with glioblastoma multiforme: Impact of steroid treatment.
Q39256918	Increasing the safety and efficacy of chimeric antigen receptor T cell therapy
Q36572920	Induction of WT1-specific human CD8+ T cells from human HSCs in HLA class I Tg NOD/SCID/IL2rgKO mice.
Q34980976	Induction of high-titer IgG antibodies against multiple leukemia-associated antigens in CML patients with clinical responses to K562/GVAX immunotherapy.
Q50026906	Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy.
Q37554202	Inferring the Impact of Regulatory Mechanisms that Underpin CD8+ T Cell Control of B16 Tumor Growth In vivo Using Mechanistic Models and Simulation
Q27023490	Inflammation, obesity, and the promise of immunotherapy for metabolic disease
Q42704100	Informed Consent: A Clinical Trials Perspective.
Q35988657	Infusing CD19-directed T cells to augment disease control in patients undergoing autologous hematopoietic stem-cell transplantation for advanced B-lymphoid malignancies.
Q35053924	Injectable, spontaneously assembling, inorganic scaffolds modulate immune cells in vivo and increase vaccine efficacy.
Q36300179	Innovative regenerative medicines in the EU: a better future in evidence?
Q64053139	Inotuzumab ozogamicin in clinical development for acute lymphoblastic leukemia and non-Hodgkin lymphoma
Q39187306	Insights into molecular therapy of glioma: current challenges and next generation blueprint
Q26830304	Integrating biological redesign: where synthetic biology came from and where it needs to go
Q104136735	Integration of mechanistic immunological knowledge into a machine learning pipeline improves predictions
Q26861559	Interleukin 12: still a promising candidate for tumor immunotherapy?
Q34177641	Interleukin-13 receptor alpha 2-targeted glioblastoma immunotherapy.
Q64275741	Interleukin-18 in Health and Disease
Q89519257	Interleukin-23 engineering improves CAR T cell function in solid tumors
Q38753216	Interleukin-33 in tumorigenesis, tumor immune evasion, and cancer immunotherapy
Q39005211	Intraperitoneal immunotherapy: historical perspectives and modern therapy
Q38424720	Intratympanic Gene Delivery of Antimicrobial Molecules in Otitis Media
Q47911139	Introduction to Cancer Stem Cells: Past, Present, and Future
Q34431441	Invariant NKT cells with chimeric antigen receptor provide a novel platform for safe and effective cancer immunotherapy
Q87954935	In Vivo Expansion and Antitumor Activity of Coinfused CD28- and 4-1BB-Engineered CAR-T Cells in Patients with B Cell Leukemia
Q37564361	Is cancer gene therapy an empty suit?
Q38098877	Is hematopoietic cell transplantation still a valid option for mantle cell lymphoma in first remission in the chemoimmunotherapy-era?
Q42373110	Is virology dead?
Q37100031	Isolation and Characterization of an HLA-DPB1*04: 01-restricted MAGE-A3 T-Cell Receptor for Cancer Immunotherapy
Q91971816	Key Features Relevant to Select Antigens and TCR From the MHC-Mismatched Repertoire to Treat Cancer
Q57961814	Killers on sterols
Q64093637	Killing Mechanisms of Chimeric Antigen Receptor (CAR) T Cells
Q47682409	Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy.
Q39064900	Kinetics of tumor destruction by chimeric antigen receptor-modified T cells
Q37500940	Koch Institute Symposium on Cancer Immunology and Immunotherapy
Q37632809	Landscape of tumor-infiltrating T cell repertoire of human cancers
Q34372167	Large-scale expansion of γδ T cells and peptide-specific cytotoxic T cells using zoledronate for adoptive immunotherapy
Q46319985	Lenalidomide Enhances the Function of CS1 Chimeric Antigen Receptor-Redirected T Cells Against Multiple Myeloma.
Q92863318	Lentiviral Vector Production Titer Is Not Limited in HEK293T by Induced Intracellular Innate Immunity
Q38147100	Lentiviral vectors for cancer immunotherapy and clinical applications
Q38389312	Lentiviral vectors in cancer immunotherapy
Q53891545	Lentivirus-Induced Dendritic Cells (iDC) for Immune-Regenerative Therapies in Cancer and Stem Cell Transplantation.
Q36031874	Lentivirus-induced 'Smart' dendritic cells: Pharmacodynamics and GMP-compliant production for immunotherapy against TRP2-positive melanoma
Q38318616	Lentivirus-induced dendritic cells for immunization against high-risk WT1(+) acute myeloid leukemia
Q52372679	Lessons learned from the blockade of immune checkpoints in cancer immunotherapy.
Q89823508	Long Non-coding RNAs: Emerging Roles in the Immunosuppressive Tumor Microenvironment
Q40095482	Long-Duration Complete Remissions of Diffuse Large B Cell Lymphoma after Anti-CD19 Chimeric Antigen Receptor T Cell Therapy
Q34508322	Long-term results of first salvage treatment in CLL patients treated initially with FCR (fludarabine, cyclophosphamide, rituximab)
Q30828860	Longitudinal PET imaging demonstrates biphasic CAR T cell responses in survivors.
Q26782902	Lymphoma Immunotherapy: Current Status
Q50034163	Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels.
Q39245218	Lymphotoxin signalling in tertiary lymphoid structures and immunotherapy.
Q100518777	L’immunologie : les bases pour comprendre les traitements actuels et à venir: Immunology: The basis for understanding current and future treatments
Q26771192	MEK inhibitors and their potential in the treatment of advanced melanoma: the advantages of combination therapy
Q92586096	Making cold malignant pleural effusions hot: driving novel immunotherapies
Q56929047	Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy
Q33993517	Managing cytokine release syndrome associated with novel T cell-engaging therapies.
Q34769213	Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents?
Q36796025	Manipulating TLR Signaling Increases the Anti-tumor T Cell Response Induced by Viral Cancer Therapies
Q34760414	Manufacture of clinical-grade CD19-specific T cells stably expressing chimeric antigen receptor using Sleeping Beauty system and artificial antigen presenting cells
Q42198836	Manufacture of gene-modified human T-cells with a memory stem/central memory phenotype.
Q36194241	Mapping of novel peptides of WT-1 and presenting HLA alleles that induce epitope-specific HLA-restricted T cells with cytotoxic activity against WT-1(+) leukemias
Q84937064	Markov model of CLL transplants
Q26749560	Marrow-Infiltrating Lymphocytes - Role in Biology and Cancer Therapy
Q37208363	Mechanisms by Which Interleukin-12 Corrects Defective NK Cell Anticryptococcal Activity in HIV-Infected Patients
Q38730881	Mechanisms of Acute Toxicity in NKG2D Chimeric Antigen Receptor T Cell-Treated Mice.
Q90218846	Mechanisms of Leukemia Immune Evasion and Their Role in Relapse After Haploidentical Hematopoietic Cell Transplantation
Q39169789	Mechanisms of Resistance to Targeted Therapies in Chronic Lymphocytic Leukemia
Q92150199	Mechanisms of resistance to CAR T cell therapy
Q28083766	Mechanistic insights into the oncolytic activity of vesicular stomatitis virus in cancer immunotherapy
Q41208517	Medical management of side effects related to CAR T cell therapy in hematologic malignancies
Q38802594	Melanoma Immunotherapy in Mice Using Genetically Engineered Pluripotent Stem Cells
Q26798404	Melanoma: From Incurable Beast to a Curable Bet. The Success of Immunotherapy
Q38773361	Mesothelin as a target for chimeric antigen receptor-modified T cells as anticancer therapy
Q37134884	Mesothelin, a novel immunotherapy target for triple negative breast cancer
Q37599478	Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies.
Q39418546	Metabolic Regulation of T Cell Longevity and Function in Tumor Immunotherapy
Q55089089	Metformin inhibits proliferation and cytotoxicity and induces apoptosis via AMPK pathway in CD19-chimeric antigen receptor-modified T cells.
Q47718243	Methods of Controlling Invasive Fungal Infections Using CD8+ T Cells.
Q38658670	Methods of ex vivo expansion of human cord blood cells: challenges, successes and clinical implications
Q47127214	Micromolar affinity CAR T cells to ICAM-1 achieves rapid tumor elimination while avoiding systemic toxicity
Q39214379	Milestones in Chronic Lymphocytic Leukemia: An exciting decade of progress-10th anniversary of memo
Q28067102	Milestones of Hematopoietic Stem Cell Transplantation - From First Human Studies to Current Developments
Q38180319	Mitigating the toxic effects of anticancer immunotherapy
Q36562453	Mitochondrial Membrane Potential Identifies Cells with Enhanced Stemness for Cellular Therapy.
Q64907480	Modeling anti-CD19 CAR T cell therapy in humanized mice with human immunity and autologous leukemia.
Q40675376	Modification of Expanded NK Cells with Chimeric Antigen Receptor mRNA for Adoptive Cellular Therapy
Q38834059	Modification of cytokine-induced killer cells with chimeric antigen receptors (CARs) enhances antitumor immunity to epidermal growth factor receptor (EGFR)-positive malignancies
Q39104849	Modification of hematopoietic stem/progenitor cells with CD19-specific chimeric antigen receptors as a novel approach for cancer immunotherapy.
Q34167797	Modular extracellular sensor architecture for engineering mammalian cell-based devices
Q50925934	Modulating the differentiation status of ex vivo-cultured anti-tumor T cells using cytokine cocktails.
Q36928580	Molecular Pathways: Breaking the Epithelial Cancer Barrier for Chimeric Antigen Receptor and T-cell Receptor Gene Therapy
Q42082214	Molecular characterization of a fully human chimeric T-cell antigen receptor for tumor-associated antigen EpCAM.
Q35666734	Molecular features of the complementarity determining region 3 motif of the T cell population and subsets in the blood of patients with chronic severe hepatitis B.
Q38117139	Molecular insights for optimizing T cell receptor specificity against cancer
Q88885438	Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells
Q37677563	Mouse models in bone marrow transplantation and adoptive cellular therapy
Q38218786	Moving receptor redirected adoptive cell therapy toward fine tuning of antitumor responses.
Q64102615	Multi Targeted CAR-T Cell Therapies for B-Cell Malignancies
Q34052580	Multifactorial T-cell hypofunction that is reversible can limit the efficacy of chimeric antigen receptor-transduced human T cells in solid tumors
Q34334598	Multifunctional T-cell analyses to study response and progression in adoptive cell transfer immunotherapy
Q47555946	Multiple Inhibitory Factors Act in the Late Phase of HIV-1 Replication: a Systematic Review of the Literature
Q34139613	Multiple chimeric antigen receptors successfully target chondroitin sulfate proteoglycan 4 in several different cancer histologies and cancer stem cells.
Q36177909	Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer
Q34047618	Multiplex Genome Editing to Generate Universal CAR T Cells Resistant to PD1 Inhibition
Q38895203	Multiplexed gene transfer to a human T-cell line by combining Sleeping Beauty transposon system with methotrexate selection
Q36452648	Multivalent porous silicon nanoparticles enhance the immune activation potency of agonistic CD40 antibody
Q91930473	My journey from tyrosine phosphorylation inhibitors to targeted immune therapy as strategies to combat cancer
Q36982805	Myeloid cells in peripheral blood mononuclear cell concentrates inhibit the expansion of chimeric antigen receptor T cells
Q50027824	NK-92 cell, another ideal carrier for chimeric antigen receptor.
Q38631020	NK-92: an 'off-the-shelf therapeutic' for adoptive natural killer cell-based cancer immunotherapy
Q36980241	NKG2D CAR T-cell therapy inhibits the growth of NKG2D ligand heterogeneous tumors
Q33595873	NKG2D CARs as cell therapy for cancer
Q27014888	NKG2D ligands as therapeutic targets
Q38656067	NLRC5/CITA: A Key Player in Cancer Immune Surveillance.
Q92766318	Nanobody-based CAR T cells that target the tumor microenvironment inhibit the growth of solid tumors in immunocompetent mice
Q38690435	Nanoscale bio-platforms for living cell interrogation: current status and future perspectives
Q95642943	Nanotechnology Promotes Genetic and Functional Modifications of Therapeutic T Cells Against Cancer
Q42562347	Nanotherapy for Cancer: Targeting and Multifunctionality in the Future of Cancer Therapies.
Q38054112	Nanovectorized radiotherapy: a new strategy to induce anti-tumor immunity
Q61818149	Natural Killer Cells and Current Applications of Chimeric Antigen Receptor-Modified NK-92 Cells in Tumor Immunotherapy
Q26745906	Natural Killer Cells for Therapy of Leukemia
Q26830512	Natural killer cell biology: an update and future directions
Q35556865	Natural killer cell engineering for cellular therapy of cancer
Q41613624	Nature of tumor control by permanently and transiently modified GD2 chimeric antigen receptor T cells in xenograft models of neuroblastoma
Q57172529	Nephrotoxicity of Cancer Immunotherapies: Past, Present and Future
Q47761448	New Approaches in CAR-T Cell Immunotherapy for Breast Cancer.
Q37344050	New approaches to manipulate minimal residual disease after allogeneic stem cell transplantation
Q33922797	New aspects of neuroblastoma treatment: ASPHO 2011 symposium review
Q93120938	New biomarkers and therapeutic strategies in acute lymphoblastic leukemias: Recent advances
Q38406089	New cell sources for T cell engineering and adoptive immunotherapy
Q35996395	New directions in cellular therapy of cancer: a summary of the summit on cellular therapy for cancer
Q38428357	New insights into the pathophysiology and therapy of adult acute lymphoblastic leukemia
Q26828496	New strategies in chronic lymphocytic leukemia: shifting treatment paradigms
Q38130615	New strategies in neuroblastoma: Therapeutic targeting of MYCN and ALK.
Q51839566	New targeted therapies for relapsed pediatric acute lymphoblastic leukemia.
Q92723315	Next generation chimeric antigen receptor T cells: safety strategies to overcome toxicity
Q35745453	Novel CD4-Based Bispecific Chimeric Antigen Receptor Designed for Enhanced Anti-HIV Potency and Absence of HIV Entry Receptor Activity
Q33874986	Novel T cells with improved in vivo anti-tumor activity generated by RNA electroporation
Q38664735	Novel Therapies for Acute Myeloid Leukemia: Are We Finally Breaking the Deadlock?
Q64097181	Novel biomanufacturing platform for large-scale and high-quality human T cells production
Q36185518	Novel cancer immunotherapy agents with survival benefit: recent successes and next steps
Q38066860	Novel cellular therapies for leukemia: CAR-modified T cells targeted to the CD19 antigen
Q26770391	Novel immunotherapeutic approaches for the treatment of acute leukemia (myeloid and lymphoblastic)
Q27004436	Novel immunotherapies for hematologic malignancies
Q26777394	Novel immunotherapies in lymphoid malignancies
Q38248461	Novel methods and approaches to acute lymphoblastic leukemia drug discovery
Q34347703	Novel recombinant human b7-h4 antibodies overcome tumoral immune escape to potentiate T-cell antitumor responses.
Q38120551	Novel targeted therapies in acute lymphoblastic leukemia
Q28069889	Novel therapeutic options in Acute Myeloid Leukemia
Q38924557	Novel therapeutic strategies in human malignancy: combining immunotherapy and oncolytic virotherapy
Q39368957	Novel therapy for childhood acute lymphoblastic leukemia
Q38925720	Obesity and cancer immunotherapy toxicity
Q100430603	Olaparib Suppresses MDSC Recruitment via SDF1α/CXCR4 Axis to Improve the Anti-tumor Efficacy of CAR-T Cells on Breast Cancer in Mice
Q57192334	Oligonucleotide Aptamer-Mediated Precision Therapy of Hematological Malignancies
Q38808628	Oncogenic roles and drug target of CXCR4/CXCL12 axis in lung cancer and cancer stem cell
Q52309503	Oncolytic viruses as engineering platforms for combination immunotherapy.
Q91907979	One-step generation of modular CAR-T cells with AAV-Cpf1
Q34307792	Opportunities and limitations of natural killer cells as adoptive therapy for malignant disease
Q36855245	Opportunities in immunotherapy of ovarian cancer.
Q40314122	Optimized depletion of chimeric antigen receptor T cells in murine xenograft models of human acute myeloid leukemia
Q40792533	Optimized human CYP4B1 in combination with the alkylator prodrug 4-ipomeanol serves as a novel suicide gene system for adoptive T-cell therapies
Q92983020	Optimizing CAR-T Cell Manufacturing Processes during Pivotal Clinical Trials
Q55224144	Optimizing EphA2-CAR T Cells for the Adoptive Immunotherapy of Glioma.
Q91964127	Optimizing Manufacturing Protocols of Chimeric Antigen Receptor T Cells for Improved Anticancer Immunotherapy
Q38840466	Optimizing T-cell receptor gene therapy for hematologic malignancies.
Q35184232	Optimizing the production of suspension cells using the G-Rex "M" series
Q35783394	Orchestrating an immune response against cancer with engineered immune cells expressing αβTCRs, CARs, and innate immune receptors: an immunological and regulatory challenge
Q34240410	Outcomes of human leukocyte antigen-matched sibling donor hematopoietic cell transplantation in chronic lymphocytic leukemia: myeloablative versus reduced-intensity conditioning regimens
Q55515652	Overcoming Resistance of Human Non-Hodgkin's Lymphoma to CD19-CAR CTL Therapy by Celecoxib and Histone Deacetylase Inhibitors.
Q64249459	Overcoming Resistance to Natural Killer Cell Based Immunotherapies for Solid Tumors
Q50027827	Overcoming barriers of car T-cell therapy in patients with mesothelin-expressing cancers.
Q38441750	Overcoming intrinsic inhibitory pathways to augment the antineoplastic activity of adoptively transferred T cells: Re-tuning your CAR before hitting a rocky road
Q38671390	Overcoming multiple myeloma drug resistance in the era of cancer 'omics'.
Q38285543	Overcoming the toxicity hurdles of genetically targeted T cells
Q38262255	Overcoming tumor-mediated immunosuppression
Q37422201	Overview of recent developments in chronic lymphocytic leukemia
Q34361637	PCR-based detection of gene transfer vectors: application to gene doping surveillance
Q36334073	PD-1 blockade enhances T-cell migration to tumors by elevating IFN-γ inducible chemokines
Q27339832	PSMA-specific CAR-engineered T cells eradicate disseminated prostate cancer in preclinical models
Q41487925	Paired Expression Analysis of Tumor Cell Surface Antigens
Q33940443	Pancreatic cancer: Hurdles in the engineering of CAR-based immunotherapies
Q38259446	Paradigm shifts in the management of poor-risk chronic lymphocytic leukemia.
Q89640744	Paradox-driven adventures in the development of cancer immunology and immunotherapy
Q26997993	Particle-mediated delivery of cytokines for immunotherapy
Q89287784	Pediatric Cancer Immunotherapy: Opportunities and Challenges
Q64097880	Peptide Super-Agonist Enhances T-Cell Responses to Melanoma
Q90690181	Performance of anti-CD19 chimeric antigen receptor T cells in genetically defined classes of chronic lymphocytic leukemia
Q38353123	Performance-enhancing drugs: design and production of redirected chimeric antigen receptor (CAR) T cells
Q37316845	Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia
Q37117624	Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy
Q89721569	Persistent Polyfunctional Chimeric Antigen Receptor T Cells That Target Glypican 3 Eliminate Orthotopic Hepatocellular Carcinomas in Mice
Q35568556	Personalized cell transfer immunotherapy for B-cell malignancies and solid cancers
Q37412148	Personalized medicine in CLL: current status and future perspectives
Q91869736	Perspective: Biophysical regulation of cancerous and normal blood cell lineages in hematopoietic malignancies
Q50875834	Perspective: assembly line immunotherapy.
Q38818283	Pharmacotherapy of relapsed/refractory chronic lymphocytic leukemia.
Q47589152	Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma
Q38787449	Phase 1 clinical trial demonstrated that MUC1 positive metastatic seminal vesicle cancer can be effectively eradicated by modified Anti-MUC1 chimeric antigen receptor transduced T cells
Q36761521	Phase 2 clinical trial of rapamycin-resistant donor CD4+ Th2/Th1 (T-Rapa) cells after low-intensity allogeneic hematopoietic cell transplantation
Q35862775	Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor-Modified T-cell Therapy for CEA+ Liver Metastases
Q92666841	Phase I Study of Lentiviral-Transduced Chimeric Antigen Receptor-Modified T Cells Recognizing Mesothelin in Advanced Solid Cancers
Q45855437	Phase I Trial of Anti-PSMA Designer CAR-T Cells in Prostate Cancer: Possible Role for Interacting Interleukin 2-T Cell Pharmacodynamics as a Determinant of Clinical Response
Q37217432	Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells
Q36475411	Phenotypic and functional attributes of lentivirus-modified CD19-specific human CD8+ central memory T cells manufactured at clinical scale
Q46214811	Phenotypic models of T cell activation
Q38012709	Phoenix rising: gene therapy makes a comeback
Q88965080	PiggyBac-Engineered T Cells Expressing CD19-Specific CARs that Lack IgG1 Fc Spacers Have Potent Activity against B-ALL Xenografts
Q96303570	Point-Of-Care CAR T-Cell Production (ARI-0001) Using a Closed Semi-automatic Bioreactor: Experience From an Academic Phase I Clinical Trial
Q36249440	Polyfunctional CD4⁺ T cells are essential for eradicating advanced B-cell lymphoma after chemotherapy
Q47550219	Posttransplant chimeric antigen receptor therapy
Q36195192	Potent and Broad Inhibition of HIV-1 by a Peptide from the gp41 Heptad Repeat-2 Domain Conjugated to the CXCR4 Amino Terminus
Q36212699	Potential therapeutic strategy for gastric cancer peritoneal metastasis by NKG2D ligands-specific T cells
Q40393182	Pre-clinical development of gene modification of haematopoietic stem cells with chimeric antigen receptors for cancer immunotherapy
Q34046041	Precision Tumor Recognition by T Cells With Combinatorial Antigen-Sensing Circuits
Q38681083	Preclinical rationale for combining radiation therapy and immunotherapy beyond checkpoint inhibitors (i.e., CART).
Q37697847	Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells
Q41909592	Preclinical validation: LV/IL-12 transduction of patient leukemia cells for immunotherapy of AML.
Q42175418	Preferential targeting of disseminated liver tumors using a recombinant adeno-associated viral vector.
Q88797021	Prevention and treatment of relapse after stem cell transplantation by cellular therapies
Q40402774	Prevention of Allograft Rejection by Use of Regulatory T Cells With an MHC-Specific Chimeric Antigen Receptor.
Q27001126	Primer on tumor immunology and cancer immunotherapy
Q34598553	Probing the effector and suppressive functions of human T cell subsets using antigen-specific engineered T cell receptors
Q37609957	Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse After Hematopoietic Stem Cell Transplantation: part III. Prevention and treatment of relapse after allogeneic transpl
Q26741260	Producer T cells: Using genetically engineered T cells as vehicles to generate and deliver therapeutics to tumors
Q35628678	Profile of elotuzumab and its potential in the treatment of multiple myeloma
Q38345576	Prognosis and therapy of chronic lymphocytic leukemia and small lymphocytic lymphoma
Q90215603	Programming CAR-T cells to kill cancer
Q36713761	Progress and challenges in viral vector manufacturing
Q26852923	Progress and prospects for engineered T cell therapies
Q38847756	Progress of dendritic cell-based cancer vaccines for patients with hematological malignancies
Q38736566	Promising immunotherapies for esophageal cancer
Q42581682	Promising therapies in multiple myeloma
Q38608986	Prospects for adoptive immunotherapy of pancreatic cancer using chimeric antigen receptor-engineered T-cells
Q49401353	Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors.
Q34507561	Prospects for gene-engineered T cell immunotherapy for solid cancers.
Q41838529	Protein design of IgG/TCR chimeras for the co-expression of Fab-like moieties within bispecific antibodies
Q57046364	Purification of mRNA Encoding Chimeric Antigen Receptor Is Critical for Generation of a Robust T-Cell Response
Q90453826	Quantitative Control of Gene-Engineered T-Cell Activity through the Covalent Attachment of Targeting Ligands to a Universal Immune Receptor
Q39405625	Quantitative Imaging Approaches to Study the CAR Immunological Synapse.
Q36683002	Quantitative high-throughput single-cell cytotoxicity assay for T cells
Q52676237	Quarter Century of Anti-HIV CAR T Cells.
Q55457286	Quo Vadis-Do Immunotherapies Have a Role in Glioblastoma?
Q61984736	RETRACTED: Steering CAR T Cells into Solid Tumors
Q63740735	RNA Viruses as Tools in Gene Therapy and Vaccine Development
Q42724344	Radiation and immunotherapy: a synergistic combination.
Q26779221	Radio-Immunotherapy-Induced Immunogenic Cancer Cells as Basis for Induction of Systemic Anti-Tumor Immune Responses - Pre-Clinical Evidence and Ongoing Clinical Applications
Q35741739	Rational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastoma
Q38071110	Rationale of anti-CD19 immunotherapy: an option to target autoreactive plasma cells in autoimmunity
Q33588711	Re-adapting T cells for cancer therapy: from mouse models to clinical trials
Q34520155	Re-directed T cells for the treatment of fibroblast activation protein (FAP)-positive malignant pleural mesothelioma (FAPME-1).
Q90084567	Real-time transfer of lentiviral particles by producer cells using an engineered coculture system
Q38045706	Reappraising the role of autologous transplantation for indolent B-cell lymphomas in the chemoimmunotherapy era: is it still relevant?
Q34789569	Reassessing target antigens for adoptive T-cell therapy
Q38763829	Recent advances and future directions in mantle cell lymphoma research: report of the 2016 mantle cell lymphoma consortium workshop
Q28078076	Recent advances and novel treatment paradigms in acute lymphocytic leukemia
Q90355383	Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management
Q28080312	Recent advances in T-cell engineering for use in immunotherapy
Q37244349	Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells
Q94503527	Receptor signaling, transcriptional, and metabolic regulation of T cell exhaustion
Q35482083	Recognition of antigen-specific B-cell receptors from chronic lymphocytic leukemia patients by synthetic antigen surrogates
Q36321176	Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma
Q58786421	Recombination of a dual-CAR-modified T lymphocyte to accurately eliminate pancreatic malignancy
Q41150808	Recurrence of melanoma following T cell treatment: continued antigen expression in a tumor that evades T cell recruitment
Q50044514	Redirected T cells in cancer therapy.
Q28553650	Redirecting Specificity of T cells Using the Sleeping Beauty System to Express Chimeric Antigen Receptors by Mix-and-Matching of VL and VH Domains Targeting CD123+ Tumors
Q45857417	Redirecting T Cells to Glypican-3 with 4-1BB Zeta Chimeric Antigen Receptors Results in Th1 Polarization and Potent Antitumor Activity
Q46550701	Redirecting T-Cell Specificity to EGFR Using mRNA to Self-limit Expression of Chimeric Antigen Receptor
Q50534081	Redirection to the bone marrow improves T cell persistence and antitumor functions.
Q38202155	Reduced intensity conditioning for allogeneic hematopoietic cell transplantation: considerations for evidence-based GVHD prophylaxis
Q41636566	Reduction of MDSCs with All-trans Retinoic Acid Improves CAR Therapy Efficacy for Sarcomas
Q28276800	Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease
Q42559059	Regimen-specific effects of RNA-modified chimeric antigen receptor T cells in mice with advanced leukemia
Q95841443	Regional Injection of CAR-T Cells for the Treatment of Refractory and Recurrent Diffuse Large B Cell Lymphoma: A Case Report
Q39329364	Regional immunotherapy for liver and peritoneal metastases
Q64999064	Regulation of CAR T cell-mediated cytokine release syndrome-like toxicity using low molecular weight adapters.
Q45950927	Regulation of T cell proliferation with drug-responsive microRNA switches.
Q38557841	Regulatory T cells: tolerance induction in solid organ transplantation
Q27025869	Regulatory T-cell therapy in transplantation: moving to the clinic
Q35886454	Regulatory considerations for clinical development of cancer vaccines
Q38777377	Relation of clinical culture method to T-cell memory status and efficacy in xenograft models of adoptive immunotherapy
Q35749986	Replication-competent retroviruses in gene-modified T cells used in clinical trials: is it time to revise the testing requirements?
Q38149916	Repositioning therapeutic cancer vaccines in the dawning era of potent immune interventions
Q47201278	Reprogramming T-cells for adoptive immunotherapy of ovarian cancer
Q42925805	Reprogramming immune responses via microRNA modulation
Q38678579	Reprogramming the oncogenic response: SET protein as a potential therapeutic target in cancer
Q35605398	Requirement of Innate Immunity in Tumor-Bearing Mice Cured by Adoptive Immunotherapy Using Tumor-Draining Lymph Nodes
Q35637089	Rescue of DNA-PK Signaling and T-Cell Differentiation by Targeted Genome Editing in a prkdc Deficient iPSC Disease Model.
Q39013616	Resistance to anticancer immunity in cancer patients: potential strategies to reverse resistance
Q49830211	Restoring Natural Killer Cell Immunity against Multiple Myeloma in the Era of New Drugs.
Q36414279	Retargeted human avidin-CAR T cells for adoptive immunotherapy of EGFRvIII expressing gliomas and their evaluation via optical imaging
Q37434670	Retargeting NK-92 cells by means of CD19- and CD20-specific chimeric antigen receptors compares favorably with antibody-dependent cellular cytotoxicity
Q38244698	Retired self-proteins as vaccine targets for primary immunoprevention of adult-onset cancers
Q41592700	Retrieval of functional TCRs from single antigen-specific T cells: Toward individualized TCR-engineered therapies
Q28074002	Retroviral vectors and transposons for stable gene therapy: advances, current challenges and perspectives
Q30580134	Reversal of tumor immune inhibition using a chimeric cytokine receptor
Q45873677	Reversible Transgene Expression Reduces Fratricide and Permits 4-1BB Costimulation of CAR T Cells Directed to T-Cell Malignancies.
Q51743858	Reversible re-programing of cell-cell interactions.
Q38945853	Review: Current clinical applications of chimeric antigen receptor (CAR) modified T cells
Q89746804	Revisiting Immunotherapy: A Focus on Prostate Cancer
Q48906344	Rewiring human cellular input-output using modular extracellular sensors.
Q36557169	Rigorous optimization and validation of potent RNA CAR T cell therapy for the treatment of common epithelial cancers expressing folate receptor
Q38186628	Rise of iPSCs as a cell source for adoptive immunotherapy
Q38575116	Role of NK cells in immunotherapy and virotherapy of solid tumors
Q89879065	Role of Non-Coding RNAs in the Development of Targeted Therapy and Immunotherapy Approaches for Chronic Lymphocytic Leukemia
Q36186619	Role of T lymphocytes in tumor response to radiotherapy
Q37606102	Role of immune cells in pancreatic cancer from bench to clinical application: An updated review
Q26748775	Role of the tumor microenvironment in mature B-cell lymphoid malignancies
Q41973053	SMAC Mimetic BV6 Enables Sensitization of Resistant Tumor Cells but also Affects Cytokine-Induced Killer (CIK) Cells: A Potential Challenge for Combination Therapy
Q50026427	Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast Cancer.
Q91774706	Safety and feasibility of virus-specific T cells derived from umbilical cord blood in cord blood transplant recipients
Q44057238	Safety and stability of retrovirally transduced chimeric antigen receptor T cells
Q47667620	Safety strategies of genetically engineered T cells in cancer immunotherapy
Q37713686	Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer
Q27022436	Science gone translational: the OX40 agonist story
Q35818365	Seatbelts in CAR therapy: How Safe Are CARS?
Q94028635	Selected Comments submitted by panelists for the August 6, 2013 Public Workshop for the IOM RAC Review Committee
Q92063627	Selective targeting of the oncogenic KRAS G12S mutant allele by CRISPR/Cas9 induces efficient tumor regression
Q91844545	Self-Assembled Multivalent Aptamer Nanoparticles with Potential CAR-like Characteristics Could Activate T Cells and Inhibit Melanoma Growth
Q90216600	Self-Assembled Nanoparticles Prepared from Low-Molecular-Weight PEI and Low-Generation PAMAM for EGFRvIII-Chimeric Antigen Receptor Gene Loading and T-Cell Transient Modification
Q40167916	Serial Activation of the Inducible Caspase 9 Safety Switch After Human Stem Cell Transplantation
Q37677416	Setting the target for pemphigus vulgaris therapy
Q41242075	Shedding of clinical-grade lentiviral vectors is not detected in a gene therapy setting.
Q38357127	Shifting paradigms in the treatment of chronic lymphocytic leukemia
Q27011688	Signaling at neuro/immune synapses
Q95832157	Signaling from T cell receptors (TCRs) and chimeric antigen receptors (CARs) on T cells
Q26744654	Signaling in Effector Lymphocytes: Insights toward Safer Immunotherapy
Q38203856	Significance of interleukin-13 receptor alpha 2-targeted glioblastoma therapy.
Q36938866	Simultaneous targeting of tumor antigens and the tumor vasculature using T lymphocyte transfer synergize to induce regression of established tumors in mice.
Q99604005	Single-Cell Analyses Identify Brain Mural Cells Expressing CD19 as Potential Off-Tumor Targets for CAR-T Immunotherapies
Q92959947	Single-cell Analysis of CAR-T Cell Activation Reveals A Mixed TH1/TH2 Response Independent of Differentiation
Q45849227	Single-cell multiplexed cytokine profiling of CD19 CAR-T cells reveals a diverse landscape of polyfunctional antigen-specific response
Q40714447	Site-specific integration of CAR gene into Jurkat T cells with a linear close-ended AAV-based DNA vector for CAR-T engineering
Q35648352	Sleeping Beauty Transposition of Chimeric Antigen Receptors Targeting Receptor Tyrosine Kinase-Like Orphan Receptor-1 (ROR1) into Diverse Memory T-Cell Populations
Q30535187	Sleeping beauty system to redirect T-cell specificity for human applications
Q36474226	Smart CARS: optimized development of a chimeric antigen receptor (CAR) T cell targeting epidermal growth factor receptor variant III (EGFRvIII) for glioblastoma
Q45887249	Specificity redirection by CAR with human VEGFR-1 affinity endows T lymphocytes with tumor-killing ability and anti-angiogenic potency
Q89991865	Sponsorship and Funding for Gene Therapy Trials in the United States
Q92348600	State-of-the-art for CAR T-cell therapy for chronic lymphocytic leukemia in 2019
Q37540913	Stem Cell-Derived Regulatory T Cells for Therapeutic Use in Arthritis
Q38364522	Stem cell state and the epithelial-to-mesenchymal transition: Implications for cancer therapy
Q38688055	Stem cell transplantation in multiple myeloma and other plasma cell disorders (report from an EBMT preceptorship meeting).
Q34511615	Stem memory T cells (TSCM)-their role in cancer and HIV immunotherapies
Q52691832	Strategies for Increasing Pancreatic Tumor Immunogenicity.
Q88569964	Strategies for enhancing adoptive T-cell immunotherapy against solid tumors using engineered cytokine signaling and other modalities
Q38055143	Strategies for enhancing vaccine-induced CTL antitumor immune responses
Q33655849	Strategies to genetically engineer T cells for cancer immunotherapy
Q46157495	Strong and sustained effector function of memory- versus naïve-derived T cells upon T-cell receptor RNA transfer: implications for cellular therapy
Q38527924	Structure, development, preclinical and clinical efficacy of blinatumomab in acute lymphoblastic leukemia
Q58797496	Studying cancer immunotherapy using patient-derived xenografts (PDXs) in humanized mice
Q97648307	Studying the biology of cytotoxic T lymphocytes in vivo with a fluorescent granzyme B-mTFP knock-in mouse
Q38818477	Super natural killer cells that target metastases in the tumor draining lymph nodes
Q97646320	Superior Expansion and Cytotoxicity of Human Primary NK and CAR-NK Cells from Various Sources via Enriched Metabolic Pathways
Q40782944	Superior Therapeutic Index in Lymphoma Therapy: CD30(+) CD34(+) Hematopoietic Stem Cells Resist a Chimeric Antigen Receptor T-cell Attack.
Q39413297	Suppression of murine colitis and its associated cancer by carcinoembryonic antigen-specific regulatory T cells
Q92696727	Survival outcomes and efficacy of autologous CD19 chimeric antigen receptor-T cell therapy in the patient with diagnosed hematological malignancies: a systematic review and meta-analysis
Q40740910	Sustained, localized transgene expression mediated from lentivirus-loaded biodegradable polyester elastomers
Q38805497	Synthetic biology approaches in cancer immunotherapy, genetic network engineering, and genome editing
Q35057524	Synthetic biology for therapeutic applications
Q51037564	Synthetic biology: Sensing with modular receptors.
Q90608633	Synthetic immunity by remote control
Q26826954	Synthetic therapeutic gene circuits in mammalian cells
Q91663735	Systematic review protocol: an assessment of the post-approval challenges of autologous CAR-T therapy delivery
Q64066337	Systematic testing and specificity mapping of alloantigen-specific chimeric antigen receptors in regulatory T cells
Q39006805	Systemic Immunity Is Required for Effective Cancer Immunotherapy
Q37584747	Systems approaches to human autoimmune diseases
Q39828587	T Cell Maturation Stage Prior to and During GMP Processing Informs on CAR T Cell Expansion in Patients
Q36642440	T Cell Vaccinology: Beyond the Reflection of Infectious Responses
Q37066770	T Cells Expressing CD19/CD20 Bispecific Chimeric Antigen Receptors Prevent Antigen Escape by Malignant B Cells
Q37308616	T cell activation is determined by the number of presented antigens
Q38912251	T cell immunoglobulin domain and mucin domain-3 as an emerging target for immunotherapy in cancer management
Q48188087	T cell modulation in immunotherapy for hematological malignancies
Q92245345	T cell receptor-based cancer immunotherapy: Emerging efficacy and pathways of resistance
Q40895848	T cell therapies-are T memory stem cells the answer?
Q38068003	T cell-based gene therapy of cancer
Q91522807	T cell-engaging therapies - BiTEs and beyond
Q34893030	T cells bearing a chimeric antigen receptor against prostate-specific membrane antigen mediate vascular disruption and result in tumor regression.
Q36300730	T cells engineered with a T cell receptor against the prostate antigen TARP specifically kill HLA-A2+ prostate and breast cancer cells
Q40186710	T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
Q35483599	T cells expressing a LMP1-specific chimeric antigen receptor mediate antitumor effects against LMP1-positive nasopharyngeal carcinoma cells in vitro and in vivo
Q40096913	T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma
Q46045077	T cells expressing chimeric antigen receptor promote immune tolerance.
Q37466219	T cells expressing chimeric antigen receptors can cause anaphylaxis in humans.
Q39387987	T cells redirected by a CD3ζ chimeric antigen receptor can establish self-antigen-specific tumour protection in the long term
Q39258646	T cells redirected to EphA2 for the immunotherapy of glioblastoma
Q38564461	T cells targeting NY-ESO-1 demonstrate efficacy against disseminated neuroblastoma
Q24632975	T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia
Q92932341	T lymphocytes against solid malignancies: winning ways to defeat tumours
Q26786661	T-Cell Therapy: Options for Infectious Diseases
Q18614829	T-Cells
Q52668512	T-bet promotes potent antitumor activity of CD4+ CAR T cells.
Q27678265	T-cell Receptor Specificity Maintained by Altered Thermodynamics
Q38169656	T-cell adoptive immunotherapy for acute lymphoblastic leukemia
Q26826830	T-cell and natural killer cell therapies for hematologic malignancies after hematopoietic stem cell transplantation: enhancing the graft-versus-leukemia effect
Q60933774	T-cell functionality testing is highly relevant to developing novel immuno-tracers monitoring T cells in the context of immunotherapies and revealed CD7 as an attractive target
Q42195075	T-cell immunotherapy with a chimeric receptor against CD38 is effective in eradicating chemotherapy-resistant B-cell lymphoma cells overexpressing survivin induced by BMI-1.
Q42549120	T-cell immunotherapy: looking forward
Q30491565	T-cell infiltration and clonality correlate with programmed cell death protein 1 and programmed death-ligand 1 expression in patients with soft tissue sarcomas.
Q92825957	T-cell receptor gene therapy targeting melanoma-associated antigen-A4 by silencing of endogenous TCR inhibits tumor growth in mice and human
Q89966656	T-cells with a single tumor antigen-specific T-cell receptor can be generated in vitro from clinically relevant stem cell sources
Q42228950	TALEN-mediated editing of endogenous T-cell receptors facilitates efficient reprogramming of T lymphocytes by lentiviral gene transfer
Q92285876	TEG001 Insert Integrity from Vector Producer Cells until Medicinal Product
Q37065561	TanCAR: A Novel Bispecific Chimeric Antigen Receptor for Cancer Immunotherapy
Q37137932	Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape
Q90395831	Targeted Therapies in CLL: Monotherapy Versus Combination Approaches
Q37395790	Targeted antibody-mediated depletion of murine CD19 CAR T cells permanently reverses B cell aplasia
Q34748489	Targeted cancer immunotherapy via combination of designer bispecific antibody and novel gene-engineered T cells
Q34270375	Targeted immunotherapy of cancer with CAR T cells: achievements and challenges.
Q38331701	Targeted therapy for chronic lymphocytic leukemia: current status and future directions
Q35076449	Targeted treatment for chronic lymphocytic leukemia: clinical potential of obinutuzumab
Q47850217	Targeting CXCL12/CXCR4 Axis in Tumor Immunotherapy
Q94545537	Targeting Cancer Stem Cells by Genetically Engineered Chimeric Antigen Receptor T Cells
Q38963420	Targeting Immune Checkpoints in Hematologic Malignancies
Q49290997	Targeting T-cell malignancies using anti-CD4 CAR NK-92 cells.
Q39177087	Targeting cancer stem cells by using chimeric antigen receptor-modified T cells: a potential and curable approach for cancer treatment
Q99587532	Targeting cardiac fibrosis in heart failure with preserved ejection fraction: mirage or miracle?
Q26798062	Targeting chronic lymphocytic leukemia cells in the tumor microenviroment: A review of the in vitro and clinical trials to date
Q33555573	Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity
Q39026731	Targeting high-grade B cell lymphoma with CD19-specific T cells
Q39149196	Targeting neoantigens to augment antitumour immunity
Q39381907	Targeting of 4-1BB by monoclonal antibody PF-05082566 enhances T-cell function and promotes anti-tumor activity
Q34329186	Targeting of acute myeloid leukaemia by cytokine-induced killer cells redirected with a novel CD123-specific chimeric antigen receptor.
Q35661999	Targeting of folate receptor β on acute myeloid leukemia blasts with chimeric antigen receptor-expressing T cells
Q38120535	Targeting of the tumor necrosis factor receptor superfamily for cancer immunotherapy
Q39318470	Targeting the MAGE A3 antigen in pancreatic cancer
Q47409813	Targeting the T cell receptor β-chain constant region for immunotherapy of T cell malignancies
Q34550649	Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy
Q91142708	Targeting the niche: depleting haemopoietic stem cells with targeted therapy
Q27026329	Targeting the tumor vasculature to enhance T cell activity
Q38601568	Targeting tumor suppressor genes for cancer therapy
Q38214095	Targeting tumor-necrosis factor receptor pathways for tumor immunotherapy
Q53106234	Team science on a smaller scale: Innovative ways investigators on both coasts are taking on cancer.
Q30591778	Tetramer guided, cell sorter assisted production of clinical grade autologous NY-ESO-1 specific CD8(+) T cells
Q38225542	Th17 cells in cancer: the ultimate identity crisis.
Q45419347	The Anti-Tumor Effects of M1 Macrophage-Loaded Poly (ethylene glycol) and Gelatin-Based Hydrogels on Hepatocellular Carcinoma
Q41442041	The Basics of Artificial Antigen Presenting Cells in T Cell-Based Cancer Immunotherapies
Q64118716	The Emergence of Universal Immune Receptor T Cell Therapy for Cancer
Q39115858	The Flipside of the Power of Engineered T Cells: Observed and Potential Toxicities of Genetically Modified T Cells as Therapy
Q36055223	The Impact of Graft-versus-Host Disease on the Relapse Rate in Patients with Lymphoma Depends on the Histological Subtype and the Intensity of the Conditioning Regimen
Q57492021	The Potential of CAR T Cell Therapy in Pancreatic Cancer
Q39130457	The Principles of Engineering Immune Cells to Treat Cancer
Q36547199	The Promise of Chimeric Antigen Receptor Engineered T Cells in the Treatment of Hematologic Malignancies
Q36535465	The Role of Adaptive Immunity in the Efficacy of Targeted Cancer Therapies
Q97525776	The Roles of CCR7 for the Homing of Memory CD8+ T Cells into Their Survival Niches
Q39042442	The Safety of available immunotherapy for the treatment of glioblastoma.
Q45821005	The Value of Cancer Immunotherapy Summit at the 2016 Society for Immunotherapy of Cancer 31st anniversary annual meeting.
Q47438165	The activated conformation of integrin β7 is a novel multiple myeloma-specific target for CAR T cell therapy
Q28646882	The advantages of PD1 activating chimeric receptor (PD1-ACR) engineered lymphocytes for PDL1(+) cancer therapy
Q57177485	The application of CAR-T cell therapy in hematological malignancies: advantages and challenges
Q34036213	The basic principles of chimeric antigen receptor design
Q28083266	The biology behind PI3K inhibition in chronic lymphocytic leukaemia
Q38175297	The challenge of pancreatic cancer therapy and novel treatment strategy using engineered mesenchymal stem cells.
Q53673922	The clinical potential for koff-rate measurement in adoptive immunotherapy.
Q35788245	The development of potential antibody-based therapies for myeloma
Q58695003	The efficacy and safety of anti-CD19/CD20 chimeric antigen receptor- T cells immunotherapy in relapsed or refractory B-cell malignancies:a meta-analysis
Q92124367	The emerging roles of inflammasome-dependent cytokines in cancer development
Q40478697	The epigenetic landscape of T cell exhaustion.
Q38355743	The evolving role of hematopoietic cell transplantation in chronic lymphocytic leukemia.
Q64264660	The evolving role of immuno-oncology for the treatment of head and neck cancer
Q33993529	The future is now: chimeric antigen receptors as new targeted therapies for childhood cancer
Q38775177	The future of cancer treatment: immunomodulation, CARs and combination immunotherapy
Q35832365	The ganglioside antigen G(D2) is surface-expressed in Ewing sarcoma and allows for MHC-independent immune targeting
Q104064819	The global chimeric antigen receptor T (CAR-T) cell therapy patent landscape
Q61449409	The growing role of precision and personalized medicine for cancer treatment
Q38950791	The growing world of CAR T cell trials: a systematic review
Q96952246	The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications
Q34637799	The human CD8β M-4 isoform dominant in effector memory T cells has distinct cytoplasmic motifs that confer unique properties
Q34309388	The human application of gene therapy to re-program T-cell specificity using chimeric antigen receptors
Q57961866	The immunological synapse
Q38267385	The inducible caspase-9 suicide gene system as a "safety switch" to limit on-target, off-tumor toxicities of chimeric antigen receptor T cells.
Q41551980	The inducible costimulator augments Tc17 cell responses to self and tumor tissue.
Q89515386	The long road to the first FDA-approved gene therapy: chimeric antigen receptor T cells targeting CD19
Q98164353	The model of cytokine release syndrome in CAR T-cell treatment for B-cell non-Hodgkin lymphoma
Q42370576	The new era of nanotechnology, an alternative to change cancer treatment
Q36408432	The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity.
Q26799896	The past, present and future of immunotherapy against tumor
Q38541019	The pharmacology of second-generation chimeric antigen receptors.
Q39039017	The promise of chimeric antigen receptor T cells (CARTs) in leukaemia
Q38764944	The prospects and promise of chimeric antigen receptor immunotherapy in multiple myeloma
Q58619853	The right touch: design of artificial antigen-presenting cells to stimulate the immune system
Q36584814	The role of B7 family molecules in hematologic malignancy
Q38021845	The role of antigen-specific and non-specific immunotherapy in the treatment of cancer
Q58605622	The role of biosimilars in value-based oncology care
Q92454632	The second genome: Effects of the mitochondrial genome on cancer progression
Q30243968	The shrinking role of chemotherapy in the treatment of chronic lymphocytic leukemia
Q38039112	The split nature of tumor-infiltrating leukocytes: Implications for cancer surveillance and immunotherapy
Q58924840	The swinging pendulum of cancer immunotherapy personalization
Q38831232	The therapeutic and diagnostic potential of the prostate specific membrane antigen/glutamate carboxypeptidase II (PSMA/GCPII) in cancer and neurological disease
Q59360113	The use of chimeric antigen receptor T cells in patients with non-Hodgkin lymphoma
Q57278479	Therapeutic Impact of Immune Responses in Cancer
Q58787586	Therapeutic Vaccines for Genitourinary Malignancies
Q50988785	Therapeutic cancer vaccines.
Q26779938	Therapeutic potential of CAR-T cell-derived exosomes: a cell-free modality for targeted cancer therapy
Q92749886	Therapeutic potential of CRISPR/Cas9 gene editing in engineered T-cell therapy
Q38124065	Therapeutic targeting of CD19 in hematological malignancies: past, present, future and beyond
Q34560877	Therapeutic targets for neuroblastomas
Q48355318	Therapeutically targeting glypican-2 via single-domain antibody-based chimeric antigen receptors and immunotoxins in neuroblastoma.
Q36110355	Tolerance and efficacy of autologous or donor-derived T cells expressing CD19 chimeric antigen receptors in adult B-ALL with extramedullary leukemia
Q48175410	Toll-like receptor 2 costimulation potentiates the antitumor efficacy of CAR T Cells.
Q36583710	Toll-like receptor agonist therapy can profoundly augment the antitumor activity of adoptively transferred CD8(+) T cells without host preconditioning
Q42379534	Tonic 4-1BB Costimulation in Chimeric Antigen Receptors Impedes T Cell Survival and Is Vector-Dependent
Q37113074	Toward eliminating HLA class I expression to generate universal cells from allogeneic donors
Q34240817	Toward synthetic biology with engineered T cells: a long journey just begun
Q38026409	Towards a 'cure' for IBD.
Q34640562	Towards an HIV cure: a global scientific strategy
Q38025094	Towards curative cancer immunotherapy: overcoming posttherapy tumor escape
Q36307671	Toxicities Associated With Adoptive T-Cell Transfer for Cancer
Q27008140	Toxicities of Immunotherapy for the Practitioner
Q37058104	Toxicities of chimeric antigen receptor T cells: recognition and management
Q34343346	Toxicity management for patients receiving novel T-cell engaging therapies.
Q52374505	Transcription Factor Target Gene Network governs the Logical Abstraction Analysis of the Synthetic Circuit in Leishmaniasis.
Q92765927	Transcriptome and Regulatory Network Analyses of CD19-CAR-T Immunotherapy for B-ALL
Q38839878	Translational Implications for Off-the-shelf Immune Cells Expressing Chimeric Antigen Receptors
Q34625543	Transplantation in chronic lymphocytic leukemia: does it still matter in the era of novel targeted therapies?
Q38094968	Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors.
Q39448180	Treating breast cancer with cell-based approaches: an overview.
Q38366422	Treatment for metastatic melanoma: a new and evolving era.
Q89700420	Treatment of CD20-directed Chimeric Antigen Receptor-modified T cells in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an early phase IIa trial report
Q45870820	Treatment of Patients With Metastatic Cancer Using a Major Histocompatibility Complex Class II-Restricted T-Cell Receptor Targeting the Cancer Germline Antigen MAGE-A3.
Q49843910	Treatment of Richter's Syndrome.
Q36114222	Treatment of a solid tumor using engineered drug-resistant immunocompetent cells and cytotoxic chemotherapy
Q39784230	Treatment of advanced leukemia in mice with mRNA engineered T cells
Q38573785	Treatment of chronic lymphocytic leukemia with monoclonal antibodies, where are we heading?
Q39111432	Treatment of malignant pleural mesothelioma by fibroblast activation protein-specific re-directed T cells
Q90465660	Treatment of metastatic non-small cell lung cancer with NY-ESO-1 specific TCR engineered-T cells in a phase I clinical trial: A case report
Q64891187	Treatment of patients with relapsed or refractory CD19+ lymphoid disease with T lymphocytes transduced by RV-SFG.CD19.CD28.4-1BBzeta retroviral vector: a unicentre phase I/II clinical trial protocol.
Q91768573	Treg cell-based therapies: challenges and perspectives
Q42702234	Trial Watch: Adoptive cell transfer for anticancer immunotherapy
Q26785545	Trial Watch: Adoptive cell transfer for oncological indications
Q36057432	Trial Watch: Adoptive cell transfer immunotherapy
Q47887134	Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia with Novel Targeted Agents.
Q38756750	Tumor Regression and Delayed Onset Toxicity Following B7-H4 CAR T Cell Therapy.
Q33689478	Tumor immunology and cancer immunotherapy: summary of the 2013 SITC primer
Q46090703	Tumor immunology and cancer immunotherapy: summary of the 2014 SITC primer.
Q35757397	Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs
Q91973610	Tumor-Derived Extracellular Vesicles Impair CD171-Specific CD4+ CAR T Cell Efficacy
Q64949581	Tumor-Specific Reactive Oxygen Species Accelerators Improve Chimeric Antigen Receptor T Cell Therapy in B Cell Malignancies.
Q35673845	Tumor-Targeted Human T Cells Expressing CD28-Based Chimeric Antigen Receptors Circumvent CTLA-4 Inhibition
Q41977894	Tumor-associated antigens for specific immunotherapy of prostate cancer
Q38217028	Tumor-infiltrating lymphocyte therapy for melanoma: rationale and issues for further clinical development
Q35613148	Tumor-infiltrating lymphocytes genetically engineered with an inducible gene encoding interleukin-12 for the immunotherapy of metastatic melanoma
Q34823085	Tumor-specific CD4+ T cells maintain effector and memory tumor-specific CD8+ T cells
Q50063348	Tumor-specific allogeneic cells for cancer therapy.
Q54978507	Tuning ITAM multiplicity on T cell receptors can control potency and selectivity to ligand density.
Q36218880	Tuning Sensitivity of CAR to EGFR Density Limits Recognition of Normal Tissue While Maintaining Potent Antitumor Activity
Q47709474	Two is better than one: advances in pathogen-boosted immunotherapy and adoptive T-cell therapy
Q34892977	Type I cytokines synergize with oncogene inhibition to induce tumor growth arrest
Q36075677	Type17 T-cells in central nervous system autoimmunity and tumors.
Q41774005	T cells targeting a neuronal paraneoplastic antigen mediate tumor rejection and trigger CNS autoimmunity with humoral activation.
Q38514503	Umbilical cord blood graft engineering: challenges and opportunities.
Q36746512	Umbilical cord blood transplantation supported by third-party donor cells: rationale, results, and applications
Q45872498	Unbiased Identification of T-Cell Receptors Targeting Immunodominant Peptide-MHC Complexes for T-Cell Receptor Immunotherapy.
Q40930095	Unique pulmonary antigen presentation may call for an alternative approach toward lung cancer immunotherapy
Q59326961	Universal CARs, universal T cells, and universal CAR T cells
Q39224315	Unleashing the immune response against childhood solid cancers
Q89548367	Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors
Q27011297	Using gene therapy to manipulate the immune system in the fight against B-cell leukemias
Q36747346	Using macrophage activation to augment immunotherapy of established tumours
Q55122008	Vaccination-induced skin-resident memory CD8+ T cells mediate strong protection against cutaneous melanoma.
Q39043404	Vaccine strategies for the treatment of lymphoma: preclinical progress and clinical trial update
Q30390904	Vaccines, new opportunities for a new society
Q28395507	Val-boroPro accelerates T cell priming via modulation of dendritic cell trafficking resulting in complete regression of established murine tumors
Q33586329	Vector production in an academic environment: a tool to assess production costs
Q55347731	Versatile CAR T-cells for cancer immunotherapy.
Q34045831	Versatile strategy for controlling the specificity and activity of engineered T cells
Q38188591	Viral lymphomagenesis: from pathophysiology to the rationale for novel therapies
Q36642808	Viral-mimicking protein nanoparticle vaccine for eliciting anti-tumor responses.
Q28066228	Virotherapy: cancer gene therapy at last?
Q49835983	What is the role of apheresis technology in stem cell transplantation?
Q37560324	What new immunotherapeutic techniques are currently being investigated for the treatment of melanoma?
Q64251378	When CAR Meets Stem Cells
Q58570505	Which biological systems should be engineered?
Q45117306	Whole blood interferon-γ levels predict the therapeutic effects of adoptive T-cell therapy in patients with advanced pancreatic cancer
Q38049970	Xenograft models of chronic lymphocytic leukemia: problems, pitfalls and future directions
Q28078210	Zebrafish Models of Human Leukemia: Technological Advances and Mechanistic Insights
Q39944717	Zoom Zoom: racing CARs for multiple myeloma
Q89062934	[Advances in immunotherapy of acute myeloid leukemia by using chimeric antigen receptor modified T cells]
Q52644666	[An experimental study of CD4 targeted chimeric antigen receptor modified T cell with anti-lymphoma activity].
Q89062936	[Anti-CD19 chimeric antigen receptor T cells (CART-19) for hemotological malignancies therapy]
Q50045993	[Cytotoxity of pomalidomide combined CAR-T cell for multiple myeloma cell RPMI8226 and U266].
Q88251354	[Donor- derived CD19 chimeric antigen receptor T cells for relapsed B cell malignancies after allogeneic hematopoietic stem cell transplantations]
Q90389192	[How I treat CAR-T cell therapy-related cytokine release syndrome]
Q50034111	[Immunotherapy of cancer with checkpoint inhibitors : Not only in malignant melanoma].
Q49791966	[Management of cytokine release syndrome during chimeric antigen receptor-modified T cell therapy].
Q53656857	[New immunotherapeutic approaches in oncology and hematology].
Q50026306	[Progress in clinical studies of chimeric antigen receptor engineered T cells for treatment of childhood cancer].
Q50042696	[Research progress of the side effect and application prospects of CAR-T cells in the treatment of malignant tumors].
Q49792109	[The specific cytotoxicities of chimeric antigen receptor-engineered T cells on different lymphomas].
Q39013357	mRNA Cancer Vaccines
Q47141728	mSA2 affinity-enhanced biotin-binding CAR T cells for universal tumor targeting
Q89540099	miR-155 Overexpression in OT-1 CD8+ T Cells Improves Anti-Tumor Activity against Low-Affinity Tumor Antigen

P356	DOI	10.1056/NEJMOA1103849
P3181	OpenCitations bibliographic resource ID	759426
P932	PMC publication ID	3387277
P698	PubMed publication ID	21830940

P50	author	Bruce L. Levine	Q85544154
		David L. Porter	Q110797660
		Carl H. June	Q19277113
P2093	author name string	Adam Bagg
		Michael Kalos
P2860	cites work	Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains.	Q37117781
		Stem cell transplantation for indolent lymphoma and chronic lymphocytic leukemia	Q37824996
		Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia.	Q39215504
		The cytoplasmic domain of the T cell receptor zeta chain is sufficient to couple to receptor-associated signal transduction pathways	Q41691499
		CARs on track in the clinic	Q42649114
		Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial	Q42797321
		Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo	Q42938990
		A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulation.	Q53650474
		Detailed studies on expression and function of CD19 surface determinant by using B43 monoclonal antibody and the clinical potential of anti-CD19 immunotoxins	Q68090182
		p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias	Q72626720
		Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen	Q24623215
		T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia	Q24632975
		Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2	Q29620608
		Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma	Q29622835
		Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice	Q30493889
		Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor	Q34122292
		Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity	Q34326400
		Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy.	Q34422330
		The promise and potential pitfalls of chimeric antigen receptors	Q34970378
		Acute tumor lysis syndrome in solid tumors--a case report and review of the literature	Q35091521
		Engineering lymphocyte subsets: tools, trials and tribulations	Q36140986
		A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer	Q36299662
		Outcomes after allogeneic hematopoietic cell transplantation with nonmyeloablative or myeloablative conditioning regimens for treatment of lymphoma and chronic lymphocytic leukemia	Q36384668
		Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells	Q36868712
		Immunological aspects of cancer chemotherapy	Q37039588
		A decade of rituximab: improving survival outcomes in non-Hodgkin's lymphoma	Q37054400
P433	issue	8
P407	language of work or name	English	Q1860
P921	main subject	leukemia	Q29496
		lymphoid leukemia	Q6708277
		lymphoblastic leukemia	Q18553852
P5008	on focus list of Wikimedia project	ScienceSource	Q55439927
P304	page(s)	725-33
P577	publication date	2011-08-25
P1433	published in	The New England Journal of Medicine	Q582728
P1476	title	Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia
P478	volume	365

Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia

scientific article

Reverse relations